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ABSTRACT 
The accumulation of vascular smooth muscle cells (VSMC) within the intima of the 
arterial walls and the increase in extracellular matrix they produce, contributes to 
vessel narrowing in the pathogenesis of vasoproliferative pathologies, including 
atherosclerosis and restenosis. The underlying mechanisms are increased 
proliferation and migration of VSMC from the media in the intima, caused by different 
growth factors and cytokines. An important proliferative stimulus, and likely the most 
potent chemoattractant for VSMC, is the platelet derived growth factor-BB (PDGF-
BB).  
Indirubin is an ingredient of a traditional Chinese medicine preparation, Dang Gui 
Long Hui Wan, which had been used in the treatment of various chronic diseases, 
including leukemia. Previous work in our lab has shown that indirubin-3´-monoxime 
(I3MO), a more soluble derivation, is able to inhibit PDGF-BB-induced VSMC 
proliferation. Furthermore, the compound was able to reduce neointima formation in 
vivo in a mouse model (experiment performed in cooperation with Prof. Binder, 
Medical University of Vienna). In addition, I3MO blocked phosphorylation of STATs 
without interfering with other common early signaling events. Here we show that in 
addition to its antiproliferative properties, I3MO is able to inhibit VSMC migration 
dose-dependently after stimulation with PDGF-BB. Furthermore it is able to interfere 
with early cytoskeletal rearrangements. In addition, we found that I3MO reduced 
STAT3 and STAT5b phosphorylation after stimulation with 10 ng/ml of PDGF-BB, a 
concentration leading rather to VSMC migration than to their proliferation. Moreover, 
I3MO reduced expression of promigratory STAT3 and STAT5b target genes after 
stimulation with 10 ng/ml of PDGF-BB. To further elucidate the underlying 
mechanisms of I3MO-effects, we compared I3MO to AG490, a chemical JAK2 
inhibitor, and to LiCl, a GSK-3 inhibitor. We found considerable similarities between 
AG490 and I3MO regarding their intracellular actions. Although the exact cellular 
target remains to be investigated, our studies affirm I3MO as a promising compound 
in the treatment of atherosclerosis and restenosis. 
  
 
  
 
ZUSAMMENFASSUNG 
Atherosklerose und Restenose gehören zu den vasoproliferativen Erkrankungen, die 
sich durch eine Anhäufung von glatten Gefäßmuskelzellen in der Intima auszeichnen. 
Außerdem produzieren diese glatten Gefäßmuskelzellen mehr extrazelluläre Matrix. 
Dies kann zu Gefäßverengung führen. Der Grund für die Anhäufung sind die erhöhte 
Proliferation und die Migration der glatten Gefäßmuskelzellen von der Media in die 
Intima, die von bestimmten Signalmolekülen ausgelöst werden. Dazu zählt Platelet 
derived growth factor-BB (PDGF-BB), ein Faktor, der stark mitogen wirkt und zudem 
der stärkste bekannte chemotaktische Stimulus für glatte Gefäßmuskelzellen ist. 
Indirubin ist ein Inhaltsstoff aus einer Zubereitung der traditionellen chinesischen 
Medizin, Dang Gui Long Hui Wan. Die Zubereitung wird in der Behandlung 
verschiedener chronischer Erkrankungen eingesetzt, darunter Leukämie. In unserem 
Labor ist bereits gezeigt worden, dass Indirubin-3´-monoxime (I3MO), ein besser 
wasserlösliches Derivat, PDGF-BB induzierte Proliferation von glatten 
Gefäßmuskelzellen hemmen kann. Ebenfalls konnte in Zusammenarbeit mit Prof. 
Binder von der Medizinischen Universität Wien gezeigt werden, dass I3MO die 
Bildung einer Neointima in vivo in einem Mausmodell vermindert. Schließlich hemmt 
I3MO die Phosphorylierung einiger Transkriptionsfaktoren aus der STAT-Familie, 
ohne dabei verschiedene andere bekannte Proteinkinasen zu hemmen. In dieser 
Arbeit zeigen wir nun, dass I3MO konzentrationsabhängig zusätzlich zur Proliferation 
auch die Migration von glatten Gefäßmuskelzellen hemmt. Weiters kann es frühe 
Umbauten im Zellskelett beeinflussen. Zusätzlich fanden wir heraus, dass I3MO die 
Phosphorylierung von STAT3 und STAT5b auch nach Stimulation mit 10 ng/ml 
PDGF-BB hemmen konnte, also in einer Konzentration die vorwiegend zu Migration 
von glatten Gefäßmuskelzellen führt als zu deren Proliferation. I3MO reduzierte 
weiters die Expression von migrationsfördernden Zielgenen nach Stimulation mit 10 
ng/ml PDGF-BB. Schließlich verglichen wir die intrazellulären Effekte von I3MO mit 
denen eines JAK2 Inhibitors (AG490) und mit denen eines GSK-3 Inhibitors (LiCl). Wir 
fanden deutliche Ähnlichkeiten in den Effekten von I3MO und AG490. Obwohl das 
intrazelluläre Zielprotein von I3MO noch aufgeklärt werden muss, bekräftige unsere 
Arbeit, dass I3MO ein vielversprechendes Molekül ist, das in der Behandlung von 
vasoproliferativen Erkrankungen wie Atherosklerose und Restenose eingesetzt 
werden könnte.  
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B. INTRODUCTION 
1. Background 
The accumulation of vascular smooth muscle cells (VSMC) within the intima of arterial 
walls and their increased production of extracellular matrix (ECM) leads to a reduction 
of the vessel lumen. This pathological process, called intimal thickening, occurs in 
atherosclerosis and restenosis after angioplasty, organ transplantation and in vein 
grafts. The underlying mechanisms are proliferation of VSMC and their migration from 
the media to the intima.1 Therefore, inhibiting migration and proliferation of VSMC 
might be a rational treatment for vasoproliferative diseases, including atherosclerosis 
and restenosis.2 
2. Atherosclerosis 
Atherosclerosis is characterized by intimal lesions called fibrofatty plaques, which 
protrude into and obstruct vascular lumens.3 The plaques cause flow-limiting stenoses 
and, after rupture of a plaque, thrombotic occlusions of arteries. This can lead to 
myocardial infarction, ischemic stroke and transient ischemic attacks.4 As myocardial 
infarction and stroke are leading causes of death, atherosclerosis, in westernized 
societies, is the underlying cause of about 50 % of all deaths.5 The genesis of 
atherosclerosis is still under investigation, but it has become clear that together with 
the pathological accumulation of lipids within the artery wall, also immune and 
inflammatory processes might participate in the development of atherosclerosis.6 
2.1. Development of atherosclerosis 
A normal artery consists of three layers. The innermost layer, named intima, is 
composed of a monolayer of endothelial cells and of elastic fibres. The middle layer, 
named media, consists of VSMC. The adventitia, the outer layer, is mainly composed 
of connective tissue.5  
In lesion-prone areas, such as coronary arteries, atherosclerotic lesions begin to 
develop under a damaged, dysfunctional endothelium.7 Dysfunctional endothelium is 
characterized by a decreased bioavailability of vasoprotective mediators, mainly nitric 
oxide (NO), whereas pro-atherosclerotic factors are increased.8 Possible risk factors 
for endothelium damage include high levels of low density lipoproteins (LDL), cigarette 
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smoking, hypertension, diabetes mellitus, and inherited diseases like tangier disease. 
Furthermore, elevated plasma homocysteine concentrations and infectious 
microorganisms are thought to play a role in the genesis of dysfunctional 
endothelium.9 As a primary event, LDL and other lipoproteins, diffuse through the 
,leaky endothelium and accumulate within the subendothelial space 5, where they 
become oxidized. Oxidized lipoproteins stimulate the endothelial cells to produce 
adhesion molecules and growth factors. Monocytes and T-lymphocytes adhere and 
migrate within the subendothelial space. There, the monocytes differentiate into 
macrophages and internalize oxidized lipoproteins. Subsequently, they convert into 
so-called foam cells.5,7 Macrophages or foam cells fail to return to blood circulation10 
and accumulate. Together with VSMC they form fatty streaks.11 Macrophages 
internalize oxidized LDL until they die by apoptosis or necrosis, leaving the lipid 
behind as extracellular lipid droplets. The advanced lesion, called atheroma, is 
characterized by a confluent core of extracellular lipid, caused by dead foam cells and 
atherogenic lipoproteins.7 With disease progression, layers of fibrous connective 
tissue can replace the intima and the lesions can calcify. The most advanced types of 
atherosclerosis are fissures, hematoma and thrombi.11,12 
2.2. The role of vascular smooth muscle cells in atherosclerosis 
Whereas in a healthy vessel only few VSMC reside in the intima, they become 
present in early fatty streaks. In advanced lesions they constitute the principal cell 
type in the intima.13 
Normally, VSMC are fully differentiated and show a low proliferation rate,14 but in 
response to atherogenic stimuli they can switch from the quiescent “contractile” state 
to the active “synthetic” state. Synthetic muscle cells migrate from the media to the 
intima and begin to proliferate.15 If the stimuli continue for years, vascular smooth 
muscle cells can thicken the artery wall, which is compensated by dilation of the 
vessel, a term called “remodeling”.13 The thickening caused by proliferation of VSMC 
leads to loss of vessel lumen and limited blood flow. Hence, ischemia might follow.7 
Furthermore, synthetic VSMC seem to promote atherosclerosis by synthesizing more 
extracellular matrix (ECM). Cultured synthetic VSMC were seen to produce between 
25 and 30-fold the amount of ECM as contractile-state cells.16 The increased 
deposition of ECM makes the vessel wall more susceptible to changes in the flow 
characteristics of the blood and to fissuring or ulceration.13 Furthermore, the 
constitution of the ECM in atherosclerotic lesions is altered: whereas within a healthy 
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artery type І and type ІІІ fibrillar collagen are predominant, atherosclerotic vessels 
contain proteoglycans with scattered type І collagen fibrils and fibronectin.17 
Proteoglycans bind several molecules necessary for lipid accumulation, calcification, 
and thrombosis.13,18 Additionally, proliferation of VSMC is up-regulated when VSMC 
bind to fibronectin and proteoglycan.17 
Moreover, VSMC take up lipids and form foam cells like macrophages. They seem to 
contribute to the retention of monocytes and macrophages within the lesion via 
expression of adhesion molecules and to have an antiapoptotic effect on them.16,17 
Finally, smooth muscle cells produce a lot of atherogenic cytokines that attract and 
activate leukocytes, induce proliferation of SMCs, promote endothelial cell dysfunction 
and stimulate production of extracellular matrix components. The most important of 
which are platelet derived growth factor (PDGF), transforming growth factor-β (TGF-
β), macrophage inhibitory factor (MIF), interferon-gamma (IFN-γ) and monocyte 
chemoattractant protein-1 (MCP-1).17 
However, some aspects of the role of VSMC in atherosclerosis are still being 
controversially discussed. The fibromuscolar cap, created by VSMC and their 
extracellular matrix in advanced lesions, seems to be important for the so-called 
plaque-stability: stable plaques with small lipid core and covered by a thick 
fibromuscolar cap tend to create occlusion and stenosis. Unstable, vulnerable plaque 
(characterized by a large lipid core and a thin fibrous cap) usually leads to rupture and 
thrombosis.10 VSMC apoptosis might represent a further cause for plaque rupture.19 
Thus, VSMC seem to play a protective role in mature plaque.7 Recently, also the 
origin of VSMC in the intima has been newly hypothesized: experimental data 
suggested that they may not derive from the media, but from progenitor cells 
originated in the bone marrow.20 Finally, the magnitude of proliferation of VSMC in 
human atherosclerotic lesions has been discussed: some studies report abundance of 
proliferation while others report very low proliferation rates.21 The low proliferation rate 
may be concordant with a greater role for migration from the media to the intima.13 
Fig. 1 gives an overview of the development of atherosclerosis and the migration of 
VSMC. 
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Fig. 1. The development of atherosclerosis.  
LDL particles diffuse through dysfunctional endothelium and become oxidized. Macrophages and T-
lymphocytes migrate within the intima, ingest oxidized LDL, and convert into foam cells. VSMC move 
from the media to the intima and proliferate, leading to advanced lesions and stenosis. Lesions may 
calcify and thrombi may form. Figure adopted from Madamanchi et al 22., for abbreviations see section 2. 
2.3. Diagnosis and treatment of atherosclerosis  
Advanced atherosclerotic lesions can be diagnosed with invasive coronary 
angiography or intravascular ultrasonography. Noninvasive technologies, like cardiac 
computed tomography or positron emission tomography, allow to detect the 
atherosclerotic plaques.23 
Up to now, no specific drug therapy has been found to prevent the formation of 
atherosclerosis lesions. Therefore, the primary and secondary prevention of 
atherosclerosis includes risk factor modification with therapeutic lifestyle changes (diet 
improvement, smoking cessation, and physical activity) as well as drug therapy with 
non-atherosclerosis-specific drugs, including acetylsalicylic acid, statins, angiotensin-
converting enzyme inhibitors and β-blockers. Thrombolysis is used in patients with 
acute cardiovascular events.24 
Furthermore, physically invasive methods are used in case of vessel constriction. The 
method utilized in case of moderate constriction is percutaneous transluminal 
angioplasty (PTA).25 In PTA , a catheter is advanced towards the stenosis and then 
inflated to press the plaque into the arterial wall.24 It is used in coronary stenosis as 
well as in peripheral stenosis, including renal and carotid stenosis.26 Furthermore, a 
bare metal stent or a drug-eluting stent, can be deployed in the stenosed section. The 
first PTA was conducted on a carotid artery by Grüntzig and colleagues in 1977. Since 
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then, PTA has revolutionized revascularization. In coronary artery disease, 
percutaneous coronary intervention (PCI) has become the most common 
intervention.27 
Other mildly invasive treatments are the removal or pulverization of the plaque with 
atheroablative technologies. The fully invasive approach, the coronary artery bypass 
grafting, is used for treating the most severe coronary artery blockages or after a heart 
attack.25  
As described above, VSMC and their migration are highly involved in the progress of 
atherosclerosis. Thus, the development of strategies to inhibit VSMC migration has 
been a major focus in the search for specific drugs capable of preventing 
atherosclerosis and restenosis, which is described in the next section.15 
3. Restenosis 
During all invasive treatments of atherosclerosis a mechanical injury of the vessel wall 
occurs. A common vessel response is lumen loss, a process called restenosis. 
Restenosis is defined as a loss of more than 50 % of the lumen diameter 28, but the 
process can even lead to complete reocclusion of the vessel.29 Restenosis is the 
major drawback after PCI,30 occurring between 30 % and 50 % in patients treated with 
balloon angioplasty and in 10-30 % of patients who receive a bare-metal stent.27 
In balloon angioplasty, the three stages of restenosis are early passive elastic recoil, 
followed by negative vascular remodeling with adventitial thickening and, 
subsequently, neointima formation due to VSMC migration and proliferation. Although 
stents prevent recoil and adventitial thickening, they are unable to prevent neointima 
formation.27  
The molecular mechanisms leading to restenosis are incompletely understood, but 
they are thought to be a maladaptive response of the vessel to trauma.27 The process 
begins with thrombus formation after injury. Subsequently, the pathology develops 
similarly to atherosclerosis: leucocytes adhere and release factors to stimulate VSMC 
migration, proliferation, and ECM production.28 Balloon angioplasty of the rat carotid 
artery is a common animal model to investigate the consequences of neointimal 
formation after mechanical injury. The arteries are distended with a balloon and the 
endothelium is removed. Mural thrombi are formed and the VSMC proliferate within 48 
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hours of injury. Subsequently, they migrate to the intima and proliferate again, leading 
to a thickened intima consisting of VSMC and connective tissue matrix.13  
To prevent neointimal formation, drug-eluting stents have been developed. They 
deliver antimitotic or antimicrotubular agents such as sirolismus and paclitaxel, 
thereby inhibiting proliferation and migration.31 As they are directly placed in the 
stenosed section, the local drug level is maximized, while the systemic toxicity is 
minimized.30 Numerous clinical data clearly showed drug-eluting stents superior to 
bare-metal stents in reducing restenosis and the number of new revascularization 
even in high-risk patients.28,32  
Therefore, inhibiting proliferation and migration represents a critical importance in 
neointima formation. Consequently, the search for new substances represents a 
challenge of active research. 
4. Migration of vascular smooth muscle cells 
VSMC migration is regulated by numerous stimuli released by macrophages, T-
lymphocytes, platelets, endothelial cells and VSMC.33 Three terms are used to 
describe cell migration after stimulation: chemokinesis is defined as an undirected 
increase in motility independent of a concentration gradient, whereas a directed 
motion toward a concentration gradient is called chemotaxis. Finally, haptotaxis is 
defined as directed migration along a path of varying adhesiveness of the ECM.31  
Cell migration is a common phenomenon in organisms. In addition to atherosclerosis 
and restenosis, it also occurs in embryonic development, in renewal of skin and 
intestine, in tissue repair, immune response and in several pathologic processes, 
including cancer.34,35 Different cell types show different characteristics of migration but 
share some basic mechanisms. Basic features are valid also for VSMC. 
4.1. Cell migration 
Migration can be seen as a cyclic process, which starts with the polarization of the cell 
after stimulation of cell surface receptors by migration-promoting factors.34,36 
Polarization implies that signaling events at the front of the cell (the leading edge) and 
the back of the cell (the trailing edge) differ.34 It is accompanied by remodeling of 
microtubules and localization of the microtubule organizing centre (MTOC) and Golgi 
apparatus in front of the nucleus.34,37 The small G protein Cdc42 and its effector 
complex PAR6/PAR3/aPK, active at the leading edge, are involved in these 
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processes.34,37,38 Another polarized molecule is PIP3: while it is produced by 
phosphatidylinositol 3-kinase (PI3K) at the front (see section 5.1.1.), it is removed by 
the phosphatase PTEN at the rear of the cell.34,39 
Once the cell is polarized, it starts to protrude toward the stimulus. Protrusions of cells 
are based on changes in their cytoskeleton, which is thought to occur by a 
“treadmilling mechanism”. Whereas the barbed end of an actin filament grows fast by 
forced actin polymerization, the pointed end grows slower due to increased 
depolymerization. This mechanism allows inherent membrane protrusion. The cells 
can form large, broad lamellipodia, where filaments organize in a branching network, 
or spike-like filopodia, where filaments form long parallel bundles.34,36,40 The functions 
of the two forms are different: filopodia act as sensors, whereas lamellipodia provide a 
strong foundation for the directional movement of the cells.37 In a later phase of 
migration, actin filaments organize also into stress fibres, which may serve for 
maintaining cells straight under tension.41 
Several proteins are involved in actin elongation. Protrusion at the barbed end is 
mediated by the actin-related protein 2/3 complex (Arp2/3), which binds to the side of 
actin filaments and induces the formation of new daughter filaments. Arp2/3 is 
activated by WASP/WAVE (Wiskott-aldirch syndrome protein/Verprolin-homologous 
protein), which in turn are targets of the small G proteins Rac and Cdc42, 
respectively.34,36,38,40 In addition, formins (mDia1/mDia2) promote linear filament 
extension, they are activated by the small G proteins RhoA and Cdc42.38,39 Profilin 
binds actin monomers and targets them to the barbed end, whereas cofilin induces 
depolymerization at the pointed end. Capping proteins terminate filament elongation, 
providing the flux of actin monomers to non-capped filaments.34,36,40 As Ena/Vasp-
proteins and the formin mDia2 are enriched at the tip of filopodia; they seem to have a 
crucial role in the unbranched continuous elongation of filaments.34,36 
For driving the cell forward, a newly formed protrusion must adhere by focal contacts 
to the surroundings.34 During migration, adhesions assemble at the leading edge and 
disassemble at the trailing edge. Furthermore, the new focal contacts at the leading 
edge can either disassemble during advancement of protrusion, a process called 
adhesion turnover, or mature into larger focal adhesions, as observed in less motile 
cells.38 Rac and Rho seem to be strongly involved in these processes.35  
Integrin-receptors are crucial in the genesis of new adhesions.34,36 They link actin 
filaments to the ECM.35 Integrin activation is bidirectional; whereas components of the 
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ECM bind to integrins from outside, other molecules, such as talin, are intracellular 
activators.15,34 The binding leads to activation of signaling cascades and to integrin 
clustering.34,37 Integrin clustering promotes a sequential addition of adhesion proteins, 
including vinculin, tensin, paxillin and, later, α-actinin.31,36 
It is not clear which mechanisms regulate the focal contact either to mature or to 
disassemble, but adhesion turnover seems to be regulated by interaction of focal 
adhesion kinase (FAK) with Src family tyrosine kinase (Src) and the adaptor proteins 
Cas and Crk, by small G proteins and by extracellular signal-regulated kinase 
(ERK).34,38 Although the major components of focal contacts have been described 
also in VSMC, the exact regulation of proteins remains mostly undefined.31  
Whereas focal contacts are necessary as traction sites, the traction force to drive the 
cell forward derives from the actin filaments interacting with myosin II. Myosin II is 
activated by myosin light chain kinase (MLCK) or Rho-associated kinase (ROCK) and 
negatively regulated by MLC phosphatase (MLCP). MLCK is activated by intracellular 
Ca2+ concentration and by a number of kinases, which are mostly regulated by Ras, 
Rac and Cdc42. ROCK is activated by the small G protein RhoA.34,38,39 In VSMC, 
basic features in traction force generation are known, but regulating details are still to 
be defined.31  
The migration cycle is concluded as the rear retracts and adhesions at the trailing 
edge disassemble. It is thought that the same mechanisms as in the front act also at 
the rear, including FAK, Src and ERK.34,35,38 Moreover, the physical tension created by 
myosin II may be enough to break the linkage between actin filaments and ECM.34 
The phosphatase calcineurin, the protease calpain as well as endocytosis of adhesion 
molecules also seem to be involved in rear disassembling.34,38 Fig. 2 shows the model 
of a migrating cell. 
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Fig. 2. Schematic illustration of a migrating cell.  
During migration, cells form spike-like filopodia and broader lamellipodia for membrane protrusion. Stress 
fibres stabilize the cell body and focal contacts serve as traction sites. For further explanations, see 
section 4.1. Figure adopted from Le Clainche and Carlier.36 
4.2. Signaling pathways involved in VSMC migration  
Migration is promoted by multiple signaling pathways activated by receptor tyrosine 
kinases (RTK), G protein-coupled receptors and integrins.31,34 Among others, small G 
proteins, Src, PI3K, mitogen-activated protein kinases (MAPK), and FAK seem to play 
a pivotal role in migration-activating signaling. They are presented in the next section. 
(5.1.) 
Furthermore, the small G protein family, including Ras, Rho, Rac and Cdc42, seems 
to be crucial for migration.39 In VSMC, especially the role of Rho and Rac as 
promoters of cell migration is well described.42-47 Small G proteins can be activated by 
both RTK and G protein-coupled receptors. Activation is promoted by guanine 
nucleotide exchange factors (GEFs), which change GDP in GTP, whereas inactivation 
is mediated by GTPase-activating proteins (GAPs).48 The most important functions of 
small G proteins were highlighted above. (See section 4.1.) 
Several of the signaling proteins involved in cell migration play also a role in VSMC 
migration. The detailed mechanisms of regulation of migration are not known, but 
some of the pathways are now understood. They are presented in fig. 3. 
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Fig. 3. Signaling pathways involved in VSMC migration.  
For explanations and abbreviations see sections 4.1. and 5.1. Figure adopted from Gerthoffer.31 
4.3. Stimuli involved in VSMC migration  
In a healthy vessel wall, VSMC do not migrate and their focal contacts are highly 
adhesive to the intact matrix.31,33 Tissue inhibitors of metalloproteinases (TIMPs) 
inhibit matrix degradation and, along with other factors such as heparin, they suppress 
VSMC migration.15,31 VSMC start to migrate in vivo when promigratory prevail 
antimigratory stimuli, as it occurs in atherosclerotic lesions and after vascular injury.31 
VSMC migration is induced by factors produced by macrophages, T-lymphocytes, 
platelets, endothelial cells and VSMC themselves.33 Furthermore, ECM components, 
sheer stress, and matrix stiffness can influence VSMC migration.31 
Probably the most important chemoattractant for VSMC is PDGF-BB, one of the three 
isoforms of platelet derived growth factor (PDGF). This growth factor is crucial for 
VSMC migration; it is therefore described in section 5. Other examples of 
chemoattractants associated with VSMC migration are basic fibroblast growth factor 
(bFGF), transforming growth factor (TGF), epidermal growth factor (EGF), insulin-like 
growth factor-1 (IGF-1) and, likely, angiotensin II.15,33 Furthermore, a variety of 
cytokines, for example tumor necrosis factor-β (TNF-β) and some interleukins, 
promote VSMC migration.31 Also components of the ECM, including laminin, 
fibronectin, vitronectin, thrombospondin, hyaluronic acid and osteopontin stimulate 
VSMC migration. As already mentioned, ECM is produced more and in an altered 
form in atherosclerotic lesions and after vessel injury.15,31,33 Finally, proteinases, like 
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urokinase plasminogen activator (uPA) and matrix metalloproteinases (MMPs), are 
responsible for VSMC migration, as they degrade the ECM barrier.15 
Most of the listed molecules have been found to stimulate migration in vitro. Thus, 
defining their role in vivo and completing the list of responsible agents, still remains a 
topic of research.31  
5. The role of PDGF in VSMC migration  
As mentioned above, PDGF-BB is the most potent chemoattractant and mitogen for 
VSMC in vitro, and inhibiting the interaction between PDGF and its receptor prevents 
PDGF-induced migration.49 Several studies confirm its important role also in vivo in 
atherosclerosis and restenosis.33 A major source of PDGF-BB in atherosclerotic 
lesions are activated macrophages, but it is secreted also by endothelial cells and 
VSMC.50 
PDGF-BB is one of the three biologically active forms of the PDGF family.51 These 
proteins are composed of two highly homologous peptide chains, PDGF-A and PDGF-
B; they form PDGF-AA, PDGF-AB and PDGF-BB.52 Recently, PDGF-CC and PDGF-
DD, which have to be activated by proteases after secretion, have been discovered.51 
Two PDGF-receptors have been described so far: α- and β-receptor. As they dimerize 
after PDGF-binding, three possible combinations emerge:  αα-, αβ- and ββ-receptor 
dimers. PDGF-AA induces solely αα-receptor dimers, PDGF-AB and PDGF-CC 
induce αα- and αβ-receptor dimers and PDGF-DD induces αβ- and ββ-receptor 
dimers. PDGF-BB is the universal inducer of all three combinations.51,52  
The PDGF family has several important functions in vivo, including embryonic 
development, wound healing, maintenance of the interstitial fluid pressure, tonus 
regulation of blood vessels, and probably also the regulation of feedback mechanisms 
in platelet aggregation.52 In addition to its role in atherosclerosis and restenosis, 
PDGF is involved in many pathological processes, including rheumatoid arthritits, 
pulmonary fibrosis, myelofibrosis, and abnormal wound repair.50 
As PDGF mediates proliferation, migration and cell survival in many different cell 
types51, evidence is growing that the different isoforms of PDGF ligand and receptor 
may mediate distinct cellular functions.33 For example, in VSMC PDGF-BB and 
PDGF-AB have been reported to be chemotactic, whereas the effects of PDGF-AA 
have been less clear. At least in vitro, PDGF-AA showed no chemotactic effects on 
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VSMC of several species. It even seemed to antagonize migratory effects of PDGF-
BB.33,53 These features and the finding that VSMC in atherosclerotic lesions show 
higher levels of β-receptors, support the idea that β-receptors promote directed 
migration, whereas α-receptors may negatively regulate chemotaxis.33,50 
Interestingly, it has been suggested that PDGF-BB principally leads to VSMC 
migration rather than to their proliferation. This has been confirmed by several 
studies.13 For instance, infusion of PDGF-BB and tritiaded thymidine in rats subjected 
to carotid injury led to neointima formation. Within the neointima, the number of 
labeled, proliferated cells was less than the number of unlabeled, thus migrated 
cells.54  
5.1. Signaling pathways of PDGF 
The PDGF-receptor becomes activated when PDGF binds to two receptors 
simultaneously and brings them together. The receptors are part of the RTK family, 
and thus approximation leads to transphosphorylation between the two receptor 
chains. Through these autophosphorylation events, the receptors activate 
downstream signaling molecules. They interact with specific domains of proteins, 
mainly the src homology 2 (SH2) domains, which recognize phosphorylated tyrosine 
residues.50,52  
Several SH2 domain containing molecules have been shown to interact with either α- 
and/or β-PDGF-receptors. Among the most important are PI3K, phospholipase C-γ 
(PLC-γ), Src, the tyrosine phosphatase SHP-2, GTPase-activating protein for Ras, the 
Janus kinases (JAKs), the signal transducers and activators of transcription (STATs) 
and Grb2. All of them have been shown to be important for proliferation, migration 
and/or cell survival. Furthermore, several SH2-domain-containing adaptor molecules 
with partly unknown functions bind to the PDGF-receptor, including Fer, Shc, Nck, 
Grb7, Grb10, Grb14 and Crk.52 Fig. 4 gives an overview of some important signaling 
proteins activated by PDGF. 
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Fig. 4. Overview of important signaling pathways activated by the PDGF-receptor.  
Binding of PDGF leads to PDGF-receptor (PDGFR) dimerization and to the activation of several signaling 
cascades. For further explanations and abbreviations see section 5.1. Figure adopted from Kang.55  
Although most of the proteins are activated by both α- and β-PDGF-receptors, some 
have a higher affinity for or bind only one receptor type.52 Furthermore, Ca2+ 
mobilization is much higher after stimulation of β-receptors than of α-receptors. Ca2+ 
activates MLCK and myosin II and might therefore be important in VSMC migration.31 
Most of the signaling pathways induced by PDGF were found also in VSMC56, and 
there were attempts to classify them in migration- or proliferation-inducing signaling 
proteins. However, it is clear that not one single pathway, but rather a cross-talk 
between different signaling molecules and pathways leads to the different cell 
responses.50 Until now, the processes are not completely understood. 
5.1.1. Phosphatidylinositol 3-kinase 
Phosphatidylinositol 3-kinase (PI3K) consists of a catalytic and a regulatory subunit. 
Both, the α- and the β-PDGF-receptor, can activate some isoforms of this kinase, 
which are able to phosphorylate the inositol ring of phosphatidylinositol-4,5-
bisphosphate (PIP2) at position three, producing phosphatidylinositol-3,4,5-
trisphosphate (PIP3).57 PI3K is implicated in the stimulation of cell growth, inhibition of 
apoptosis and cell migration.52 It activates different proteins important for cell 
migration, including members of the small G protein family like Rho, Rac and Cdc42, 
the serine/threonine kinase Akt, members of PKC family, the c-Jun N-terminal kinase 
(JNK) and FAK.15,33,52,58 PI3K interacts with Ras, and therefore seems to be an 
upstream activator of MAPK.15  
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In VSMC, the role of PDGF-induced PI3K activation is not clear. It seems to be 
necessary in PDGF-induced VSMC proliferation57,59, but inhibition of PI3K was hardly 
or not capable of antagonizing PDGF-induced migration of some VSMC types.31,57-60 
In his review, Gerthoffer supposed that the highly efficacious stimulus PDGF-BB 
activates a variety of signaling pathways and thus the inhibition of one component 
might not be enough to keep a VSMC from migrating.31  
5.1.2. Phospholipase C-γ 
Both, the α- and the β-PDGF-receptor, are able to bind members of the 
phospholipase C-γ (PLC-γ). Like PI3K, PLC-γ uses PIP2 as substrate and converts it 
into inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG activates 
proteinkinase C (PKC), an enzyme phosphorylating other intracellular proteins, while 
IP3 leads to calcium release from stores located in the endoplasmatic reticulum.61 
Furthermore, PLC-γ seems to be involved in the activation of phospholipase D 
(PLD)52,56, Na+/H+ exchanger 52 and FAK 58.  
PLC-γ has been shown to be important in both migration and proliferation.50,52 Also in 
VSMC, binding of PDGF leads to phosphatidylinositol turnover; PIP2 levels decrease, 
whereas the concentrations of DAG and Ca2+ rise.50 Nevertheless, it is still an open 
question whether PLC-γ is important in VSMC proliferation or migration. In rabbit 
aortic smooth muscle cells, PDGF-BB-induced migration was reported to occur at 
concentrations lower than those needed for detectable PLC-γ activation.62 On the 
other hand, Liu et al. showed that an inhibitor of the phosphatidylinositol-specific PLC 
family antagonized PDGF-induced proliferation and migration.57 
5.1.3. Src family of tyrosine kinases 
Src family is characterized by a non-receptor kinase domain, which normally is 
inactive because of an intrinsic suppression mechanism.63 Binding to different 
receptors, including the α- or the β-PDGF-receptor, activates the kinase.52,63 The Src 
family is associated with PDGF-mediated proliferation52, but their contribution to cell 
migration is not entirely clear.58  
VSMC express several members of the Src family, including Src, Fyn, Lyn and Yes.31 
Interestingly, in VSMC PDGF-induced activation of Src seems strongly related to 
migration and proliferation, and inhibition of Src blocks PDGF-induced VSMC 
migration and proliferation.64,65 Possible downstream targets of Src include the MAPK 
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signaling, FAK, Cas and paxillin.31 In colonic smooth muscle cells, Src and FAK were 
shown to promote PDGF-mediated Ca2+ influx and contraction.66 
5.1.4. SH2-containing protein-tyrosine phosphatase  
The SH2-containing protein-tyrosine phosphatase (SHP-2) can be activated by the α- 
or the β-PDGF-receptor. It dephosphorylates the autophosphorylated receptor and is 
therefore part of the negative feedback mechanism. However, in certain conditions, 
SHP-2 also promotes positive signaling.52 PDGF-stimulated cells do not enter the cell 
cycle when SHP-2 is blocked51, and SHP-2 may be involved in the activation of the 
MAPK signaling pathway.52 Furthermore, several studies suggest a role in PDGF-
induced-chemotaxis.58  
Studies regarding the role of SHP-2 in PDGF-stimulated VSMC are rare, but together 
with other phosphatases, SHP-2 was seen to have a negative impact on VSMC 
growth and migration.67 
5.1.5. Mitogen-activated protein kinases 
MAPK are a family of cytoplasmic serine threonine kinases, which are involved in 
transduction from extracellular signals to the nucleus.15 Their activation leads to cell 
proliferation, differentiation, survival, inflammation and apoptosis.68-70 Furthermore, 
evidence is growing that they are also essential for cell migration.70 They might be 
directly involved in vascular remodeling and diseases. In VSMC, three classes of 
MAPK have been shown to be activated by PDGF: ERK 1/2, p38 MAP kinase (p38) 
and JNK.68 
Extracellular signal-regulated kinases 1 and 2 
The extracellular signal-regulated kinases 1 and 2 (ERK1/2) become activated by their 
MAPK/ERK kinases MEK1 and MEK2, which in turn are activated by Raf. Activation of 
Raf usually requires Ras.71 Activation of Ras was shown to play a central role in 
proliferation and in migration 52. In addition to ERK 1/2, several other molecules have 
been reported to be downstream effectors of Ras, including p38 and JNK.58,70 In 
PDGF-stimulated cells, Ras is activated by the nucleotide exchange factor Sos-1, 
which in turn becomes activated by the adaptor molecule Grb2. Grb2 binds directly to 
the β-PDGF-receptor and probably also to the α-PDGF-receptor.52  
In VSMC, the activation of ERK1/2 is associated rather with proliferation than with 
migration.50 Nevertheless, their importance in migration has been shown in several 
studies in the last years. For example, antisense oligonucleotides against ERKs as 
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well as the infection of VSMC with a dominant negative mutant of ERK resulted in 
decreased VSCM migration after PDGF stimulation.68,72 The downstream signals of 
ERK providing VSMC migration are not clear; they may include MLCK, FAK and 
calpain.70 
p38 MAP kinase 
PDGF induces also the activation of p38 MAP kinase (p38) 68, which becomes directly 
activated by MAPK kinases (MKK), including MKK3, MKK6 and others.69 P38 has 
been associated with inflammation (for example via increased production of 
proinflammatory cytokines), proliferation and apoptosis.73 In addition, several studies 
suggest an important role in migration.70  
Also in VSMC, the activation of p38 is thought to contribute to migration. Infection of 
VSMC with a dominant negative mutant of p38 as well as the treatment with p38 
inhibitors reduced PDGF-induced VSMC and other smooth muscle cell migration.68,74 
However, not all p38 inhibitors have been reported to inhibit PDGF-stimulated 
migration of VSMC.75 MAPK activated protein kinase 2 (MK2) and its effector protein, 
the heat shock protein 27, have been reported to be necessary elements in 
downstream signaling of p38 in PDGF-induced smooth muscle cell migration.74 
c-Jun N-terminal kinase 
In addition, PDGF and other extracellular stimuli activate c-Jun N-terminal kinase 
(JNK) via JNK kinases, including MKK4 and MKK7. Interestingly, also Rac, FAK, Src 
and Cas seem to activate JNK.69 Like other MAPK, JNK has been associated with 
inflammation, cell survival, proliferation and apoptosis.76 Several studies demonstrate 
the important role of JNK also in cell migration.70  
In VSMC, the role of JNK is less investigated than the role of p38 and ERK.31 Infection 
of VSMC with a dominant negative mutant of JNK as well as the treatment with JNK 
inhibitors reduced PDGF-induced VSMC migration 68, but further studies are needed 
to address the role of JNK. Also the downstream effectors remain to be elucidated; 
paxillin has been proposed as a possible effector protein.31  
5.1.6. Focal adhesion kinase 
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase localized at 
focal contacts and adhesions.70 As part of a cytoskeleton-associated protein complex, 
including Src, Cas, Grb2 and Shc, it links integrin receptors to intracellular signaling 
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pathways.58,77 (See also section 4.1.) The exact function of FAK is unknown, but its 
implication in cellular migration was investigated in numerous studies.60,62,77-80 FAK 
has been reported to be phosphorylated after PDGF stimulation62, and its 
phosphorylation has been found to be essential for PDGF-induced migration.77 The 
downstream effectors of FAK are incompletely understood, they may include paxillin.60  
Also in VSMC, FAK seems to play an important role in migration. FAK and paxillin 
have been found to be phosphorylated at lower concentrations than those needed for 
stimulation of other PDGF targets, like PLC-γ and PI3K. Increased phosphorylation 
correlated with the chemotactic response to PDGF. 62 Furthermore, overexpression of 
the endogenous inhibitor FAK-related-nonkinase suppressed PDGF-induced 
migration in VSMC.81 
5.1.7. Janus kinase/ Signal transducers and activators of transcription 
The signal transducers and activators of transcription (STATs) are a family of seven 
structurally related proteins: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and 
STAT6.82 The phosphorylation of specific tyrosine residues leads to their homo- and 
heterodimerization. After activation, STATs are rapidly translocated to the nucleus, 
where they bind to target promoters to increase expression of several genes, 83 
including immediate early genes, such as c-myc and c-fos, as well as cell cycle 
regulatory genes, such as cyclins.84  
A large number of cytokines, growth factors and ligands for G protein-coupled 
receptors are able to induce STAT activation.82 In contrast to most growth factor 
receptors, cytokine receptors often do not have an intrinsic tyrosine kinase activity. 
Therefore, receptor-associated Janus kinases (JAKs) provide the phosphorylation of 
STATs.83 After ligand binding, the receptors undergo a conformational change, which 
brings two JAKs together allowing autophoshorylation and consecutive activation of 
STATs. Four classes of JAKs are known so far: JAK1, JAK2, JAK3 and TYK2.82  
At least STAT1, STAT3 and STAT5 can be directly activated by the PDGF-
receptor.52,85 Furthermore, several studies suggest that PDGF-receptors can activate 
STATs via JAKs.82 For example, Vignais et al. showed that JAK1, JAK2 and TYK2 
became phosphorylated after PDGF stimulation and were found to be associated with 
the receptor.86 Furthermore, it has been suggested that Src52 and reactive oxygen 
species84 could be involved in activation of STATs after PDGF stimulation. Finally, 
several MAPK phosphorylate STATs on serine residues leading to their full activation; 
therefore they are supposed to unify both JAK- and MAPK-signaling cascades.84 The 
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JAK/STAT-signaling cascade is inactivated by classical feedback loops; STATs up-
regulate the expression of suppressor of cytokine signaling (SOCS), which inactivate 
JAKs.83  
Due to the fact that STATs are transcription factors, they are crucial for a wide array of 
biological functions, including the regulation of proliferation, survival, differentiation 
and transformation.84 Primarily in knock-out mice studies it has been shown that all 
STATs are very important in promoting an efficient immune response after cytokine 
stimulation.82 Constitutive activation of STAT3, STAT5a and STAT5b and the loss of 
activation of STAT1 has been found to be involved in cancer development.87  
Furthermore, STATs seems to be involved in the development of vascular diseases.88 
For instance, it has been shown that balloon injury of a rat carotid artery induced 
JAK2-, TYK2-, STAT1- and STAT3 expression and STAT3 phosphorylation.89 
Moreover, overexpression of a dominant negative STAT3 in a balloon injured artery 
resulted in reduced proliferation and neointima formation.90 A similar study with similar 
results was done with STAT5b, indicating that also STAT5b might be involved in 
VSMC proliferation and migration.91  
A few studies exist regarding the effects of STAT activation after PDGF stimulation. In 
VSMC, it has been demonstrated that the JAK2/STAT3-axis is important in vascular 
smooth muscle growth. Induction of cytosolic phospholipase A2 (cPla2) was increased 
after PDGF stimulation and this seemed to be mediated by the STAT3/JAK2-axis. 
cPla2 is thought to be a major source of eicosanoid metabolites, which play an 
important role in cell proliferation and survival.92 In addition, the Jak2/STAT3-axis was 
shown to be necessary for VSMC migration. Transfection of VSMC with dominant 
negative JAK2 and STAT3 resulted in significantly decreased motility. Also in this 
study, cPla2 was found to be an important effector molecule.93Although no studies 
exist regarding the role of STAT3 in human vascular smooth muscle cells, it was 
demonstrated that PDGF stimulates proliferation of human airway smooth muscle 
cells via JAK/STAT3 activation.84  
Also STAT5b has been found to be activated after PDGF stimulation of VSMC. 
Transfection with dominant negative STAT5b reduced VSCM proliferation and motility. 
In addition, expression of cyclin D1 was seen to be induced by STAT5 after PDGF 
stimulation.91 Taken together, these studies suggest that STAT3 and STAT5b are 
important in VSMC migration, but further studies are needed to clarify the exact 
pathways, the upstream activators and the downstream effectors.  
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6. Indirubin 
The discovery of indirubin goes back to a traditional Chinese medicine preparation, 
Dang Gui Long Hui Wan, a mixture of eleven herbal components. In the traditional 
Chinese medicine it is used as a therapeutic principle to “purge the fire of liver and 
gallbladder”. It has been used in the treatment of various chronic diseases, including 
hypertension, mania, convulsions, hypochondriac pain, and leukemia.94 In 1967, the 
efficiency of Dang Gui Long Hui Wan in the treatment of chronic myelocytic leukemia 
was shown in a clinical study; Qing dai was discovered as the active ingredient.95  
Qing Dai, the Chinese name of indigo naturalis, is listed in the Chinese 
pharmacopoeia as a haemostatic, antipyretic, anti-inflammatory and sedative 
medicine. Furthermore, it is used in the treatment of bacterial and viral infections. It 
can be obtained from various dyed plants including Baphicacanthus cusia, Indigofera 
suffruticosa, Indigofera tinctoria, Polygonum tinctorium or Isatis indigotica.96,97 Initially, 
the main constituent of Qing Dai, the well known blue dye indigo, was associated with 
its antileukemic properties, but further investigations revealed the red colored indirubin 
as the responsible principle.98 Clinical trials followed showing indirubin as an effective 
agent in the treatment of chronic myelocytic and chronic granulocytic leukaemia.96  
6.1. Origin of indigoids 
In addition to plants, the bis-indoles indigo and indirubin can be found in mollusks and 
in the urine of patients suffering from various diseases, including acute 
myelomonocytic leukemia, porphyrinuria, and purple urine bag syndrome.99,100 Both 
compounds can also be detected in the urine of healthy persons.100 In plants, 
indigoids form from indoxyls in dead organic material. The hydroxy-groups of indoxyl-
precursor substances are released by enzymatic or acidic hydrolysis. Subsequently, 
free indoxyl is oxidized to isatin; isatin and indoxyl dimerize and form the blue indigo, 
the red-brown isoindigo and the red indirubin. At present, indigo and indirubin are 
mainly obtained by synthesis.101  
6.2. Derivatives of indirubin 
Although indirubin was generally well-tolerated in clinical trials, some patients had to 
stop the treatment because of severe side effects in the gastrointestinal tract.95 
Hence, a lot of indirubin analogues have been designed in the last years, with the aim 
to create derivatives with increased solubility, cellular efficacy and selectivity. Figure 5 
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presents the structures of indirubin and a range of the most frequently used indirubin 
derivatives.102  
 
 
Fig. 5. Structures of indirubin and some of the most frequently used indirubin derivatives.  
Figure adopted from Meijer et al.102 
6.3. Molecular targets of indirubin 
Several molecular targets of indirubin have been found in the last years. Among the 
most important are cyclin-dependent kinases (CDKs), glycogen synthase kinase-3 
(GSK-3), aryl hydrocarbon receptor (AhR), glycogen phosphorylase , JNK, Src, and 
STAT3.102 
6.3.1. Cylin-dependent kinases 
Cyclin-dependent kinases (CDKs) are the catalytic subunits of a family of 
serine/threonine kinases, which are essential for the control of cell cycle events, 
transcription, and neuronal function.103 A small group of the numerous CDK family 
triggers cell cycle progression and cell cycle regulation.103 They are activated by 
associated proteins, the cyclins, which are synthesized and degraded during each cell 
cycle. 
Briefly, the cell cycle can be divided into G1-phase, where proteins needed for DNA 
replication are synthesized, S-phase, where DNA is duplicated, G2-phase, where the 
cell prepares for mitosis, and M-phase, where two identical nuclei form.104 Transition 
from the resting state G0-phase into G1-phase and the early G-phase are mediated 
by cyclin D/CDK4-complex and cyclin D/CDK6-complex.96,103 Transition to S-phase is 
mediated by cyclin E/CDK2-complex.96,103 During S-phase-progression, CDK2 
associates with cyclin A.97,103 Cyclin A, together with CDK1, triggers then S-phase and 
G2-phase.97,103 Subsequently, cyclin B associates with CDK1 to drive the cell through 
M.96,103 CDK-activating kinase (CAK) is believed to phosphorylate all cell cycle CDKs. 
It is a protein complex formed of CDK7, Cyclin H and Mat1.103  
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Indirubin and three derivatives, including indirubin-3´-monoxime (I3MO), were shown 
to inhibit CDK1, CDK2, CDK4 and CDK5 in cell-free kinase assays. The crystal 
structure of CDK2 in complex with indirubin derivatives showed that the kinases were 
inhibited via interaction of indirubins with their ATP-binding site, through van der 
Waals interactions and three hydrogen bonds.105 Other studies confirmed this 
finding.102 A plentitude of studies investigating the effects of I3MO and its derivatives 
on numerous cancer cell lines 98,105-108 and in vivo studies109 followed. It has been 
found that I3MO and its derivatives can induce cell cycle arrest in all cancer cell lines 
investigated, with exception of adenocarcinoma cells.105 Furthermore, 5´-substituted 
I3MO derivatives have been found to induce significant inhibition of tumor growth in 
rat tumor models.109 The cells have been found to be mainly arrested in G2/M-
phase98,105,107, at least at higher concentrations of I3MO and derivatives; but also the 
arrest in other cell cycle phases has been shown.98,105-107 In addition, I3MO, and 
especially its derivatives, induced apoptosis in several cell lines and in vivo tumor 
models, but the rate differed from cell type to cell type.98,105-109  
Decreased activity of CDK1 and decreased concentration of cyclin B/CDK1 complex 
has been found in mammary carcinoma cells after incubation with I3MO98, while 
reduced levels of cyclin B/CDK2 and cyclin D/CDK4 have been reported in oral 
carcinoma cells after incubation with 5-nitro-I3MO.107 In addition, I3MO and 
derivatives have been shown to induce also CDK inhibitors, for example p16107 and 
p21.106-108 Also, indirubins have been found to activate classical apoptotic signaling 
molecules, including p53, which mediates cell cycle arrest through induction of CDK 
inhibitors108 and members of the caspase-cascade.106,107,109 On the other hand, 7-
bromo-I3MO has been shown to induce apoptosis independent of classical 
pathways.110 Taken together, these results indicate that I3MO and its derivatives may 
be interesting anticancer agents. Their exact action on CDK inhibition remains to be 
elucidated.  
In addition to its anticancer activity, I3MO was found to inhibit CDK9, the catalytic 
subunit of a transcription factor essential for HIV-1 replication, in a cell-free kinase 
assay. Furthermore, it inhibited HIV-1 replication in leucocytes at concentrations that 
did not affect cell proliferation.111 
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6.3.2. Glycogen synthase kinase-3 
The glycogen synthase kinase-3 (GSK-3) family is evolutionarily related to CDKs and 
consists of three members discovered so far: GSK-3α, GSK-3β and a splice variant of 
GSK-3β.99,112 The isoforms show close homology in their kinase domains, and little is 
known about isoform-specific functions.112 The ubiquitously expressed serine-
threonine kinase shows four interesting properties. First, it is constitutively active.113 
Second, phosphorylation of an N-terminal serine by several proteins, including Akt, 
Proteinkinase A or C and others, leads to inactivation of GSK-3, whereas 
phosphorylation of a tyrosine residue leads to its activation. The tyrosine residue 
activation might occur by autophoshorylation or by other kinases, but little is known 
about them.112 Third, phosphorylation of substrates by GSK-3 leads generally to their 
inactivation.113 Finally, GSK-3 substrates need to be “pre-phosphorylated” by other 
kinases to be phosphorylated by GSK-3.112,113  
GSK-3 has been reported to phosphorylate more than 50 proteins in vitro114, including 
metabolic and signaling proteins, structural proteins and transcription factors.112 Thus, 
it contributes to the regulation of crucial cellular functions, such as apoptosis, cell 
cycle, cell polarity and migration, gene expression, and others.114  
For many years, the kinase has been thought to be strongly related to glycogen 
metabolism. It phosphorylates and thus inactivates glycogen synthase, an enzyme 
implicated in the conversion of glucose to glycogen.113,115 Among other mechanisms, it 
is thought that increased GSK-3 activity causes insulin resistance and diabetes, by 
reducing the clearance of glucose from blood.115 Today, GSK-3 is also known to be 
involved in other diseases, including Alzheimer´s disease, cancer and 
inflammation.113,114,116 GSK-3 inhibitors are currently being developed for various 
diseases.113  
In Alzheimer´s disease, GSK-3 seems to be responsible for the hyperphosphorylation 
of tau, a protein implicated in the formation of neurofibrillary tangles.117 Furthermore, 
β-amyloid, a protein responsible for the formation of neuronal plaques, is thought to 
activate GSK-3.118 
The role of GSK-3 in cancer formation is less clear. It is known that GSK-3 is centrally 
involved in the Wnt signal transduction pathway. Wnts play essential roles in cell 
proliferation, differentiation and motility. Within this pathway, GSK-3 serves to 
phosphorylate β-catenin, thereby targeting it for degradation and inhibiting 
transcription of Wnt target genes.116,119 Mutations of proteins in the Wnt signaling 
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pathway have been linked to numerous types of human cancer. Thus, it has been 
thought that GSK-3 inhibition could mimic tumorgenesis.119 However, studies on the 
role of GSK-3 in oncogenesis are contradictive and its action may be cell type-
dependent.120 In their review, Patel and Woodgett even proposed GSK-3 inhibitors as 
selective anticancer agents.116  
Moreover, GSK-3 seems to have an important role in inflammation. It was shown to 
be necessary for proinflammatory cytokine production in peripheral immune cells121 
and to stimulate the immune response of microglia, including migration.122  
Generally, GSK-3 has been found to influence all stages of cell migration, including 
dynamics of actin cytoskeleton, microtubule and adhesion turnover. For instance, 
GSK-3 has been seen to activate small G proteins, including Rac, Rho and ADP-
ribosylation factor 6 (Arf6).123 However, the specific signaling pathways are not clear. 
Its effects may depend from time and place of action and may be also cell type 
specific.114 In contrast, some studies reported a promigratory effect of inhibited GSK-
3: it was proposed that Cdc42 phosphorylates and thus inhibits GSK-3 locally in 
astrocytes, thereby allowing the adenomatous polyposis coli protein (APC) to promote 
microtubules dynamics.124 On the other hand, inhibition of total cellular GSK-3 
suppressed migration of several cell types, including intestinal epithelial cells125, 
kidney epithelial cells126, epidermal keratinocytes127, and axon elongation in 
neurons.128 Due to these results it could be expected that inhibition of GSK-3 may also 
suppress VSMC migration. 
However, expression of a constitutively active, nonphosphorylatable mutant of GSK-3 
reduced VSMC migration toward growth factor stimuli, including PDGF.129 In the few 
existing studies and reviews about the role of GSK-3 in VSMC, GSK-3 was found to 
suppress proliferation and to induce apoptosis. Growth factors, including PDGF, were 
found to phosphorylate and to inactivate GSK-3, thus reversing these effects.130,131 
Finally, expression of a constitutively active mutant of GSK-3 in rats was reported to 
reduce neointima formation in rats.132  
Indirubin and some of its derivatives, especially I3MO and 5-iodo-I3MO have been 
shown to inhibit GSK-3 even more potently than CDKs in cell-free kinase assays. 
Similar to CDK inhibition, I3MO acts as a competitive inhibitor of ATP binding to GSK-
3.99 In Alzheimer´s disease models, I3MO was demonstrated to suppress tau 
phosphorylation in vitro and in vivo, likely due to inhibition of GSK-3 and CDK5.105 
Furthermore, a GSK-3 selective I3MO derivate, 6-bromo-I3MO, decreased 
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phosphorylated tau protein levels, and total tau protein levels.133 In addition, the 
blockage of GSK-3 by I3MO prevented loss of dopamine neurons in a Parkinson 
disease mouse model, suggesting an important role of the kinase also in this 
disorder.134 Finally, I3MO suppressed Notch-1 activation, a protein implicated in cell-
fate decisions, in a GSK-3-dependent manner in human embryonic kidney cells.135  
6.3.3. Other targets of indirubin  
Although indirubins have been mostly described as GSK-3 and CDK inhibitors, there 
are some reports about other molecular targets. The aryl hydrocarbon receptor (AhR) 
is a ligand-activated transcription factor that regulates genes involved in xenobiotic 
metabolism, cellular proliferation, and differentiation. Although a number of xenobiotic 
compounds, including dioxin, have been found to interact with AhR, the physiological 
ligands are unknown. In a yeast reporter assay, indigo and indirubin have been 
identified as AhR ligands present in normal human urine.100 A subsequent in vivo 
study confirmed this finding, but indirubins have been found to be clearly less potent 
than in vitro.136 A number of AhR target genes up-regulated after indirubin stimulation 
have been identified, including cytochrome p 450-enzymes136,137 and the CDK inhibitor 
p27.138 Up-regulation of p27 has been found to induce cell cycle arrest. Interestingly, 
the effects of indirubin on AhR and CDK seemed to be independent, as kinase-
inactive indirubin derivatives strongly interacted with AhR and induced cell cycle arrest 
in G1-phase.138 Thus, the interaction with AhR might further contribute to the 
antiproliferative properties of indirubins.  
Moreover, crystal structure analyses have demonstrated that indirubin-5-sulphonate 
binds to the purin inhibitor site of glycogen phosphorylase, an enzyme implicated in 
glycogen degradation.139 In cell-free kinase assays, I3MO has been found to inhibit 
serum- and glucocorticoid-induced kinase (SGK), AMP-activated protein kinase 
(AMPK) and lymphocyte kinase (LCK).140 In computational approaches, 7-substituted 
I3MOs have been shown to inhibit Aurora B and C, kinases involved in mitosis.141 JNK 
has been shown to be inhibited by I3MO in cell-free kinase assays and the inhibition 
of JNK seemed to be responsible for increased c-Jun phosphorylation and thus 
apoptosis in cerebellar granule neurons.142 Finally, I3MO inhibited Src kinase and 
JAK-1 kinase in vitro and suppressed constitutive STAT3 signaling due to inhibition of 
Src kinase in human cancer cells.143  
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7. Aim of the work 
In her PhD thesis Andrea Schwaiberger showed that I3MO inhibits PDGF-induced 
VSMC proliferation dose-dependently, arresting them in G0/G1-phase. Furthermore, 
she found a selective complete inhibition of STAT1/STAT3/STAT5b phosphorylation 
and a partial inhibition of STAT6 phosphorylation after stimulation with PDGF-BB. 
Other early signaling protein kinases, including p38, ERK and Akt were not affected.  
In addition, in collaboration with Univ.-Prof. Dr. Bernd Binder from the Department of 
Vascular Biology and Thrombosis Research (Medical University of Vienna), she 
showed a significantly reduced neointima formation in a cuff-induced neointima 
mouse model.144  
However, some interesting questions about I3MO regarding its cellular actions 
remained open. Therefore, we asked whether the compound is able to inhibit PDGF-
BB-induced VSMC migration as well. Additionally, we wanted to investigate whether 
inhibition of STATs by I3MO might be responsible for impaired VSMC migration. To 
further elucidate the underlying signaling pathways, we compared cellular actions of 
I3MO to other protein inhibitors, including the JAK2 inhibitor AG490 and the GSK-3 
inhibitor LiCl.  
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C. MATERIALS AND METHODS 
1. Materials 
Unless otherwise noted, all cell culture reagents were obtained from Lonza Group Ltd. 
(Basel, Switzerland). All other reagents were obtained from Carl Roth (Karlsruhe, 
Germany). Laurent Meijer from CNRS (Roscoff, France) kindly provided indirubin-3´-
monoxime (I3MO).  
Growth factors  
Name Conc. used Provider 
recombinant human PDGF-BB 10 ng/ml Bachem (Weil am Rhein, Germany) 
Table I. Growth factors  
PDGF-BB was dissolved in sterile aqua bidest. (10 %) and sterile PBS + 0.2 % BSA 
(90 %) to a concentration of 10 ng/µl, and stored at -20 °C. Prior of use it was diluted 
with DMEM to a final concentration of 1 ng/µl. For abbreviations see also chapter H, 
section 1. 
Protein inhibitors 
Name Conc. used Provider 
I3MO 3 µM, 5 µM Meijer (CNRS, Roscoff, France) 
LiCl 10 mM, 20 mM Carl Roth (Karlsruhe, Germany) 
AG490 25 µM, 50 µM Calbiochem (La Jolla, CA, USA) 
Table II. Protein inhibitors  
Protein inhibitors were dissolved in DMSO and stored at -80 °C.  
1.3. DNA cross linker 
Name Conc. used Provider 
Mitomycin C 2.5 nM–25 µM Calbiochem (La Jolla, CA, USA) 
Table III. DNA cross linker  
Mitomycin C was dissolved in DMSO. 
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1.4. Antibodies 
Primary Antibodies Source Dilution used Provider 
α-tubulin Mouse, mc 1:2500 SC 
Cyclin A  Rabbit, pc 1:1000 SC 
Cyclin D1 Mouse, mc 1:1000 NEB 
cPLA2 Rabbit, pc 1:500 NEB 
Phospho-ERK1/2 Y202/204 Rabbit, pc 1:1000 NEB 
Phospho-p38 Y180/182 Rabbit, pc 1:1000 NEB 
Phospho-STAT3 Y705 Rabbit, pc 1:1000 NEB 
Phospho-STAT5 Y694 Rabbit, pc 1:1000 CS 
Secondary Antibodies Source Dilution used Provider 
HRP-linked rabbit IgG goat 1:2500 CS 
HRP-linked mouse IgG goat 1:2500 US 
Abbreviations 
mc 
pc 
SC 
NEB 
CS 
HRP 
US 
 
Monoclonal 
Polyclonal 
Santa Cruz (Santa Cruz, CA, USA) 
New England Biolabs (Beverly, MA, USA)N 
Cell signaling (Danvers, MA, USA) 
horseradish peroxidase 
Upstate (Charlottesville, VA, USA) 
Table IV. Antibodies  
Antibodies were diluted in 5% BSA in TBS-T. 
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2. Methods 
2.1. Cell culture 
Cell culture media   
Growth medium Calf serum 
L-glutamine 
Penicillin 
Streptomycin 
in DMEM 
10 % 
2 mM 
100 U/ml 
100 µg/ml 
Starvation medium Calf serum 
L-glutamine 
Penicillin 
Streptomycin 
in DMEM 
0.1 % 
2 mM 
100 U/ml 
100 µg/ml 
Freezing medium Calf serum 
L-glutamine 
Penicillin 
Streptomycin 
DMSO 
in DMEM 
30 % 
2 mM 
100 U/ml 
100 µg/ml 
10 % 
Cell culture buffers   
PBS, pH 7.4 NaCl 
Na2HPO4 
KH2PO4 
in aqua dest. 
123.2 mM 
10.4 mM 
3.5 mM 
 
Cell culture reagents   
Trypsin/ EDTA in PBS Trypsin (Invitrogen, Carlsbad, CA, USA) 
EDTA 
in PBS  
0.05 % 
0.02 % 
 
Abbreviations 
DMEM 
DMSO 
PBS 
EDTA 
 
Dulbecco´s Modified Eagle Medium 
Dimethyl sulfoxide 
Phosphate buffered saline  
Ethylenediaminetetreacetic acid  
Table V. Cell culture media, buffers and reagents  
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Cell isolation 
VSMC were kindly provided by Irene Sroka. They originate from rat thoracic aortas of 
sibling Sprague-Dawley rats. For isolation protocol see reference.145 Cells obtained 
from early passages (3-6) were frozen in liquid nitrogen. 
Cell cultivation 
VSMC were cultured in growth medium at 37 °C and 5 % CO2.They were grown to a 
nearly confluent cell layer and passaged twice per week. For passaging, cells were 
washed with PBS and trypsinized with Trypsin/EDTA for three minutes. Subsequently, 
growth medium was added and the cells were centrifuged for 4 min at 1400 rpm 
(373xg). The cell pellet was re-suspended in growth medium and the cells were 
counted with a trypan-blue staining based cell viability analyzer (VicellTM XR, 
Beckmann Coulter, Fullerton, CA, USA). Cells were seeded in flasks, in 6- or 12-well 
plates or in 6 mm dishes and grown to designated density. Passages 6-14 were used 
for experiments. Prior to experiments, VSMC were cultured with starvation medium for 
24 h-48 h. 
Storage 
Cells were trypsinized, centrifuged at 1400 rpm (373xg/4min/4 °C), and re-suspended 
in freezing medium. Cryovials with 1x106 cells were kept at 4 °C for 20 min. 
Subsequently, they were frozen at -20 °C for 1 day and at -80 °C for 2-3 days and 
then transferred into liquid nitrogen. For unfreezing cells, they were thawed, put in 
growth medium and centrifuged (1400 rpm/4 min). The cell pellet was dissolved in 
growth medium again and seeded in cell culture flasks. 
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2.2. Protein extracts 
Protein extract buffers    
Lysis buffer 
  Stock solution, pH 7.5 
 
 
 
 
 
 
  Prior to use  
 
HEPES 
NaCl 
NaF 
Na4P2O7x10H20 
EDTA 
Na3VO4 
in aqua dest. 
Stock solution 
PMSF (0,1 M in isopropanol) 
ComleteTM 25x 
Triton X-100 (10% in aqua dest.) 
 
50 mM 
50 mM 
50 mM 
10 mM 
5 mM 
1 mM 
 
430 µl 
5.0 µl 
20 µl 
50 µl 
SDS sample buffer (3x buffer) 
  Stock solution 
 
 
 
 
  Prior to use: 
 
TRIS- HCL pH 6.8 0,5 M 
SDS 
Glycerol 
Bromophenol blue 
in aqua dest. 
Stock solution 
2-Mercaptoethanol 
 
0.19 M 
0.21 M 
4.10 M 
0.22 mM 
 
85% 
15% 
Protein quantification solution Rotiquant© (20 %in aqua bidest.)  
Abbreviations 
HEPES 
PMSF 
SDS 
 
Hydroxyethylpiperazineethanesulfonic acid 
Phenylmethanesulphonylfluoride 
Sodium dodecyl sulfate 
Table VI. Protein extraction reagents 
Protein extraction 
0.9 x 106 cells were seeded in 60 mm dishes, cultured for 24 h at 37 °C, 5 % CO2 and 
serum-starved for 24 hours prior to experiment. Subsequently, they were 
preincubated with protein inhibitors (I3MO, LiCl, AG490) or vehicle (DMSO 1 %) for 30 
min and stimulated with 10 ng/ml of PDGF-BB for 10 min. Cells were washed three 
times with ice-cold PBS and treated with lysis buffer (10 min/4 °C). Cells were scraped 
off and lysats were centrifuged (16000xg/10 min/4 °C). Supernatants were diluted with 
sample buffer (1:3) and heated to 95 °C (5 min). Samples were stored at -20 °C. 
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Protein quantification 
For protein quantification after extraction a Bradford assay was performed.146 The 
method is based on the shift of the absorbance maximum of Commassie Brilliant Blue 
G-250 from 470 nm to 595 nm after binding to basic or aromatic amino residues. A 
small amount of supernatant of each protein sample was diluted 1:10 in aqua bidest 
and triplicates of 10 µl were transferred in a 96-well plate. Subsequently, 190 µl of 
diluted Rotiquant© was added and absorbance was measured at 595 nm with a 
Tecan sunrise™ microplate reader. For protein quantification, a standard curve with 
increasing concentrations of BSA (50-500 ng/µl) was prepared. 
2.3. SDS-polyacrylamide gel electrophoresis 
Electrophoresis puffer TRIS-base  
Glycine 
SDS  
in aqua dest. 
250 mM 
1.92 M 
35 mM  
SDS page gels   
Stacking gel  
  Freshly prepared: 
 
 
 
 
  Addition prior to use: 
 
PAA  
(stock: 30 % acrylamid, 0.8 % bisacrylamid) 
TRIS HCl pH 6.8 
SDS (10 %) 
Aqua dest. 
TEMED 
APS (10 %) 
 
640 µl 
 
375 µl 
37.5 µl 
2.62 ml  
7.5 µl 
37.5 µl 
Resolving gel 
  Freshly prepared: 
 
 
 
 
  Addition prior to use: 
 
PAA (stock: see stacking gel) 
TRIS HCl pH 8.8 
SDS 
Aqua dest. 
TEMED 
APS (10 %) 
 
1.875 ml 
1.875 µl 
75 µl 
3.05ml  
7.5 µl 
37.5 µl 
Abbreviations 
PAA 
TRIS 
TEMED 
APS 
 
Polyacrylamide 
Trihydroxymethylaminomethane 
Tetramethylethylenediamine 
Ammonium persulfate 
Table VII. SDS-PAGE reagents 
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SDS-polyacrylamide gel electrophoresis (SDS-PAGE) by Laemmli was used for 
separating proteins.147 Hereby, proteins move through a PAA-gel towards the anode 
in an electric field. The proteins are denatured and negatively charged because of 
their previous dissolution in SDS. They are separated almost only due to their size. 
Resolution gel and stacking gel were prepared in a gel chamber and an equal amount 
of protein samples (20 µg) was loaded. The gel chamber was put into electrophoresis 
chambers (Mini-Protean™, Biorad laboratories, Hercules, CA, USA) filled with 
electrophoresis buffer. Electrophoresis was performed at constant voltage (100 V), 
until the dye front reached the anode. 
2.4. Western blotting 
Western Blotting buffers 
Blotting buffer (5x buffer) 
 
 
  Dilution prior to use: 
TRIS-base 
Glycine 
in aqua dest. 
Blotting buffer 
MeOH 
Aqua dest. 
125 mM 
0.97 M 
 
20 % 
20 % 
ad 100 % 
Table VIII. Western blotting buffers and solutions 
Proteins were transferred from the PAA-gel to an Immun-Blot™ PVDF membrane 
(Biorad Laboratories, Hercules, CA, USA) using tank blotting technique. Thereby, gel 
and membrane were placed into gel holder cassettes and put into cooled blotting 
chambers (Mini-Trans-Blot™, Biorad, Laboratories, Hercules, CA, USA), filled with 
blotting buffer. They were run at constant current (110 mA/ gel for 120 min).  
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2.5. Protein detection 
Protein detection buffers and solutions 
TBS-T, pH 8 (10 x) 
 
 
 
  Dilution prior to use:  
TRIS-base 
NaCl 
Tween-20 (Addition after pH adjustment) 
in aqua dest. 
TBST 10 x 
Aqua dest. 
25 mM 
190 mM 
0.08 mM 
 
10 % 
90 % 
ECL solution 
 
 
 
  Addition prior to use 
TRIS-HCl pH 8.5 
Luminol (stock: 250 mM in DMSO) 
p-Coumaric acid (stock: 91 mM in DMSO) 
in aqua dest. 
H2O2 (stock: 30 %) 
0.1 M 
1.25 mM 
0.2 mM 
 
0.01% 
Table IX. Protein detection butters and solutions 
After blotting, membranes were washed with TBS-T (3 x 10 min), blocked with 5% 
milk powder in TBS-T and incubated with primary antibody-solutions overnight at 4 °C. 
Subsequently, membranes were washed with TBS-T (3 x 10 min), incubated with 
secondary antibody-solutions and washed again with TBS-T (3 x 10 min). Proteins 
were detected with a luminescent image analyzer (LAS-3000™, Fujifilm, Tokyo, 
Japan), using freshly prepared ECL solution. 
2.6. Wound healing assay 
For measuring migration, a wound healing assay (also named scratch assay) was 
used. For this assay, cells were first grown to a confluent cell monolayer in 6-well 
plates and serum-starved for 48 h. Using a sterile pipette tip, a small scratch was 
created. Subsequently, cells were pretreated with protein inhibitors (I3MO, LiCl, and 
AG490) or vehicle (DMSO 1 %) for 30 min and then stimulated with PDGF-BB (10 
ng/ml). Migration rate was determined by photographing the cell free area of each 
scratch immediately before and 22 h after PDGF stimulation (Olympus Live View 
Digital SLR Camera E-330, Olympus Europe Gmbh, Hamburg, Germany). For 
evaluation, Cell Profiler software was used. (Cell Profiler, Broad Institute, Cambridge, 
MA, USA, www.cellprofiler.org) To ensure that only migration, but not proliferation 
contributes to scratch re-narrowing, the assay was stopped after 22 h, whereas the 
VSMC used had a generation time of 26-28 h.145 
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2.7. Phalloidin staining 
Phalloidin staining reagents   
collagen I-solution 
 
collagen I in 0.02 N acetic acid (BD Bioscience 
Pharmingen, San Diego, CA, USA).  
 
Cytoskeleton buffer, pH 6.1 
 
 
 
 
 
NaCl 
EGTA 
MgCl2 
Glucose 
MES  
NaOH (pH adjustment to 6.1) 
150 mM 
5 mM 
5 mM 
5 mM 
10 mM 
 
Extraction buffer Triton X-100 
Glutaraldehyde  
in cytoskeleton buffer 
0.25 % 
50 % 
 
Fixation buffer Glutaraldehyde 
in cytoskeleton buffer 
1% 
 
Phalloidin solution FITC-labeled phalloidin solution (Sigma 
Aldrich, St. Louis, MO, USA) in PBS 
0.66% 
 
Abbreviations 
EGTA 
MES 
FITC 
 
Ethylene glycol tetraacetic acid 
2-N-morpholino-ethanesulfonic acid 
Fluorescein isothiocyanate  
Table X. Phalloidin staining reagents 
The phallotoxin phalloidin binds specifically to the actin cytoskeleton of cells.148 
Therefore, in this assay fluorescent-labeled phalloidin was used to visualize changes 
in actin cytoskeleton of VSMC after PDGF stimulation. For this assay, coverslips were 
placed in 12 well-plates and covered with collagen I-solution (350 µl/ml) under sterile 
conditions for 2 h at room temperature. Then, the coverslips were washed twice with 
PBS and carefully dried. 0.2 x 106 cells per coverslip were seeded on the 12 well-plate 
for 24 h, and serum-starved for another 24 h. Subsequently, cells were pretreated with 
protein inhibitors (I3MO, LiCl) or vehicle (DMSO 1 %) for 30 min and stimulated with 
PDGF-BB (10 ng/ml) for one hour. Cells were briefly rinsed with PBS, extracted with 
preheated extraction buffer for 1 min and postfixed with fixation buffer at room 
temperature for 15 min. Cells were washed with PBS for a few minutes. 
Subsequently, cells were stained with 20 µl of phalloidin solution in a dark and humid 
chamber for 30 min. Samples were kept in the dark from this step onwards. 
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Coverslips were washed with PBS three times for 5 min and then mounted with 
mounting medium (Sigma Aldrich, MO, USA) on a glass slide. Samples were 
analyzed with a fluorescence microscope (Olympus BX51, Olympus Europe GmbH, 
Hamburg, Germany) and pictures were taken with cell imaging software (cell^F 
software, Europe GmbH, Hamburg, Germany). 
2.8. Technical equipment and software 
Technical equipment  Provider 
 Vi-Cell™ XR Cell viability analyzer and cell 
counter 
Beckmann Coulter, Fullerton, CA, 
USA 
TECAN Sunrise™ 96-well-plate reader TECAN, Mannedorf, Switzerland 
LAS-3000™ Luminescent image analyzer  Fujifilm, Tokyo, Japan 
Olympus CKX31 Light microscope Olympus Europe GmbH, Hamburg, 
Germany 
Olympus Live View Dig 
SLR Camera E-330 
Camera Olympus Europe GmbH, Hamburg, 
Germany 
Software   
www.cellprofiler.org Cell migration software Broad Institute, Cambridge, MA, 
USA 
GraphPad PRISM™ 4.03 Statistical software program GraphPad Software Inc, San Diego, 
CA, USA 
Table XI. Technical equipment and software  
2.9. Statistics 
Statistical analyses were made using GraphPad PRISM™, version 4.03 (GraphPad 
Software Inc, San Diego, CA, USA). Experiments were carried out at least three times 
and data were expressed as means ± standard error (SEM). For statistical evaluation, 
one-way ANOVA followed by Dunnett post-test was used. P-value < 0.05 was 
considered statistically significant.  
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D. RESULTS 
In her PhD thesis, Andrea Schwaiberger showed an antiproliferative effect of I3MO on 
VSMC in cell culture. Furthermore, neointima formation was reduced by I3MO in a 
cuff-induced neointima mouse model.144 We wanted to learn more about the influence 
of I3MO on VSMC, concentrating on PDGF-induced migration and the signaling 
proteins inhibited by I3MO. Our interest was especially focused on a possible role of 
JAK2 and GSK-3 as targets of I3MO. 
1. Influence of I3MO, AG490 and LiCl on PDGF-BB-induced VSMC 
 migration 
1.1. Wound healing assay as a model to study PDGF-BB-induced migration 
To examine the influence of I3MO on VSMC migration, we used a wound healing 
migration assay (see chapter C, section 2.6.). For migration stimulation, we utilized 10 
ng/ml of PDGF-BB, since previous results identified this concentration as optimal to 
trigger VSMC migration.145 Fig. 6 shows the concentration-dependent influence of 
PDGF-BB on VSMC migration. Migration was stimulated from concentrations of 1 
ng/ml of PDGF-BB onwards. The migration peak was reached at 10 ng/ml, whereas 
20 ng/ml led to decreased migration. Data were generated by Mario Kumerz and Irene 
Sroka (PhDs). 
 
Fig. 6. Concentration-dependent increase in PDGF-BB-induced VSMC migration. 
Serum-starved VSMC were scratched, pretreated with DMSO 1 % for 30 min and stimulated with 
increasing concentrations of PDGF-BB (1-20 ng/ml). Cells were captured at 0 h and after 20 h. Cell free 
areas were calculated using Cell Profiler software (see chapter C, section 2.8.) Graphs show means of 
three independent experiments ± SEM. (*, p < 0.05; **, p < 0.01; one-way ANOVA followed by Bonferroni 
post-test versus PDGF treatment). Data generated by Mario Kumerz and Irene Sroka, PhDs.  
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In order to exclude that PDGF-BB-induced proliferation contributes to re-narrowing of 
the scratched area within the timeframe of the experiment, we used the DNA cross 
linker Mitomycin C, an antiproliferative agent 149 
Fig. 7 shows that 100 nM of Mitomycin C did not reduce PDGF-stimulated VSMC 
migration. Concordant with previous work150, the same concentration of Mitomycin C 
led to an increase in S-phase-arrested cells after 24 h (Fig. 7). Therefore we 
concluded that our experimental setup allowed us to study exclusively cell migration 
phenomena. Data were generated by Irene Sroka, PhD.145 
 
Fig. 7. Influence of Mitomycin C on PDGF-BB-induced VSMC migration and proliferation. 
A. Serum-starved VSMC were scratched, pretreated with Mitomycin C or vehicle (DMSO 1 %) for 30 min 
and stimulated with PDGF-BB (10 ng/ml). Cells were captured at 0 h and after 20 h. Cell free areas were 
calculated using Cell Profiler software (see chapter C, section 2.8.) Graphs show means of three 
independent experiments ± SEM. (***, p < 0.001, one-way ANOVA followed by Bonferroni post-test 
versus PDGF treatment). Data were generated by Irene Sroka, PhD. B. Serum-starved VSCM were 
pretreated with Mitomycin C or vehicle (DMSO 1%) for 30 min and stimulated with PDGF-BB (20 ng/ml). 
The percentage of cells in each cell cycle phase was determined after 20 h, using flow cytometric 
analysis of PI-stained nuclei. Graphs show means of three independents experiments. Data were 
generated by Irene Sroka, PhD.  
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1.2. I3MO inhibits PDGF-BB-induced migration of VSMC 
I3MO was shown to effectively reduce PDGF-induced proliferation.144 Since migration 
of VSMC also plays an important role in the onset of atherosclerosis and restenosis, 
we aimed to investigate a potential antimigratory effect of I3MO. We therefore 
subjected I3MO to a wound healing assay. Fig. 8 shows that I3MO (in concentrations 
of 3 µM and 5 µM) effectively reduced VSMC migration in a wound healing assay after 
stimulation with 10 ng/ml of PDGF-BB.  
 
Fig. 8. Influence of I3MO on PDGF-BB-induced migration.  
Serum-starved VSMC were scratched, pretreated with I3MO (3 µM or 5 µM) or vehicle (DMSO 1 %) for 
30 min and stimulated with PDGF-BB (10 ng/ml). Cells were captured at 0 h and after 22 h. Cell free 
areas were calculated using Cell Profiler software (see chapter C, section 2.8.). (A) Representative 
photographs of scratches. (B) Graphs show means of three independent experiments ± SEM. (**, p < 
0.01, one-way ANOVA followed by Dunnett post-test versus PDGF treatment).  
RESULTS 
47 
 
1.3. AG490 and LiCl inhibit PDGF-induced migration of VSMC 
Previous work in our lab has shown that I3MO selectively reduced STAT3 
phosphorylation on Y705 upstream of STAT3 without affecting other early-signaling 
kinases.144 The direct target of I3MO, however, has not been elucidated so far. 
STAT3 has been reported in a few studies to promote VSMC migration; and this might 
depend on its phosphorylation by an upstream kinase, JAK2.93,151 Hence, we 
hypothesized that also I3MO might reduce VSMC migration after PDGF-BB 
stimulation via inhibition of JAK2 and subsequent STAT3 phosphorylation. For 
investigating this hypothesis, we tested the effects of the tyrphostin AG490, a 
selective JAK2 inhibitor152-154 on VSMC migration after stimulation with 10 ng/ml of 
PDGF-BB. We used concentrations from 25 to 50 µM, as described in the 
literature.93,155,156 
Furthermore, I3MO has already been shown as a GSK-3 inhibitor in different cell 
types and GSK-3 has been described to be involved in migration (see chapter B, 
section 6.3.2.). Therefore, we additionally examined whether LiCl, a known GSK-3 
inhibitor 157-163, influenced VSMC migration after stimulation with 10 ng/ml of PDGF-BB 
in a wound healing assay. According to several other studies, we used concentrations 
of LiCl from 10 to 20 mM.128,164-166 Fig. 9 shows that in addition to I3MO also AG490 
and LiCl were able to potentially inhibit VSMC migration. 
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Fig. 9. Influence of LiCl and AG490 on PDGF-BB-induced migration. 
Serum-starved VSMC were scratched, pretreated with AG490 (25 µM or 50 µM), LiCl (10 mM or 20 mM) 
or vehicle (DMSO 1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml). Cells were captured at 0 h 
and after 22 h. Cell free areas were calculated using Cell Profiler software (see chapter C, section 2.8.). 
(A) Representative photographs of scratches. (B) Graphs show means of three independent experiments 
± SEM. (**, p < 0.01, one-way ANOVA followed by Dunnett post-test versus PDGF treatment). 
To exclude that only osmotic influences contribute to a decrease in VSMC migration 
after treatment with LiCl, we repeated the experiment with NaCl and MgCl2 at the 
same concentrations (10 and 20 mM). Fig. 10 shows that neither the treatment with 
NaCl nor with MgCl2 led to a similar reduction in VSMC migration after stimulation with 
10 ng/ml of PDGF-BB. 
RESULTS 
49 
 
 
 
Fig. 10. Influence of LiCl, NaCl and MgCl2 on PDGF-BB-induced migration.  
Serum-starved VSMC were scratched, pretreated with LiCl (10 mM or 20 mM), NaCl (10 mM or 20 mM), 
MgCl2 (10 mM or 20 mM) or vehicle (DMSO 1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml). 
Cells were captured at 0 h and after 22 h. Cell free areas were calculated using Cell Profiler software 
(see chapter C, section 2.8.) (A) Representative photographs of scratches. (B) Graphs show means of 
three independent experiments ± SEM. (*, p < 0.05; **, p<0.01, one-way ANOVA followed by Dunnett 
post-test versus PDGF treatment). 
Overall, these data show that both, an inhibitor of JAK2 and an inhibitor of GSK-3 
elicit an antimigratory effect in VSMC which is comparable to I3MO. 
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2. Influence of I3MO, AG490 and LiCl on STAT3/STAT5b
 phosphorylation 
In her thesis, Andrea Schwaiberger reported I3MO as an inhibitor of phosphorylation 
of STAT1 on Y701, STAT3 on Y705 and STAT5 on Y694 after stimulation with 20 ng/ml of 
PDGF-BB. Furthermore, phosphorylation of STAT 6 on Y641 was partially inhibited 
after 10 min. Phosphorylation of several protein kinases downstream of the PDGF-
BB-receptor, including ERK, p38 and Akt was not affected.144 
STAT3 and STAT5b have been shown in several studies and reviews to regulate cell 
migration167-171, including VSMC migration.91,93,151,172 We therefore repeated the 
experiment of Andrea Schwaiberger using 10 ng/ml of PDGF-BB, the concentration 
we had used to examine influences of I3MO on VSMC migration. Fig. 11 (A and B) 
shows that I3MO inhibited phosphorylation of STAT3 on Y705 and phosphorylation of 
STAT5b on Y694 also after stimulation with 10 ng/ml of PDGF-BB.  
 
Fig. 11. Influence of I3MO on PDGF-BB-induced STAT3 and STAT5b phosphorylation after 10 min. 
Serum-starved VSMC were pretreated with I3MO (3 µM or 5 µM) or vehicle (DMSO 1 %) for 30 min and 
stimulated with PDGF-BB (10 ng/ml) for 10 min. Cell lysates were prepared and subjected to western blot 
analysis for phosphorylation of STAT3 on Y705 (A) and phosphorylation of STAT5b on Y694 (B). Graphs 
show means of densitometrically analysed protein/tubulin ratios of three independent experiments ± 
SEM. (**, p < 0.01, one-way ANOVA followed by Dunnett post-test versus PDGF treatment).  
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In VSMC, it has been shown that STAT3 phosphorylation after PDGF-BB stimulation 
was JAK2-dependent.92,93 We therefore used the JAK2 inhibitor AG490 to verify 
whether phosphorylation of STAT3 on Y705 might be reduced in an I3MO-like manner. 
In addition, we investigated whether the phosphorylation of STAT5b on Y694 after 
PDGF-BB stimulation might be influenced by AG490. 
Furthermore, GSK-3 was reported to be involved in STAT3 and STAT5b 
phosphorylation in different cell types and in vivo.173,174 Therefore, we investigated the 
influence of the GSK-3 inhibitor LiCl on phosphorylation of STAT3 on Y705 and 
phosphorylation of STAT5b on Y694 after PDGF-BB stimulation for 10 min in VSMC. 
Fig. 12 (A and B) shows that LiCl was unable to reduce phosphorylation of STAT3 on 
Y705 and STAT5b phosphorylation on Y694 after PDGF-BB stimulation for 10 min. 
AG490 reduced STAT3 phosphorylation, and the reduction was significant at higher 
concentration as we had expected from literature.93 Furthermore, AG490 was able to 
reduce STAT5b phosphorylation significantly also in lower concentrations. However, 
AG490 did not abrogate STAT3 and STAT5b phosphorylation as potent as I3MO. 
 
Fig. 12. Influence of LiCl and AG490 on PDGF-BB-induced STAT3 and STAT5b phosphorylation 
after 10 min.  
Serum-starved VSMC were pretreated with AG490 (25 µM or 50 µM), LiCl (20 mM) or vehicle (DMSO 1 
%) for 30 min and stimulated with PDGF-BB (10 ng/ml) for 10 min. Cell lysates were prepared and 
subjected to western blot analysis for phosphorylation of STAT3 on Y705 (A) and phosphorylation of 
STAT5b on Y694 (B). Graphs show means of densitometrically analysed protein/tubulin ratios of three 
independent experiments ± SEM. (*, p < 0.05; **, p < 0.01, one-way ANOVA followed by Dunnett post-
test versus PDGF treatment).  
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Beurel et al. showed that the complete inhibition of STAT3 phosphorylation by LiCl 
after stimulation with interferon-γ (IFN-γ) and lipopolysaccharide (LPS) in primary 
astrocytes was reached after 1 h.173 We therefore further examined the effects of 
I3MO, LiCl and AG490 on phosphorylation of STAT3 on Y705 and STAT5b on Y694 
after stimulation with 10 ng/ml of PDGF-BB for 1 h.  
Levels of phosphorylated STAT3 were reduced by all three compounds, but AG490 
and LiCl were not as potent as I3MO. Furthermore, the difference between levels of 
phosphorylated STAT3 in PDGF-BB-treated and vehicle-treated samples was not 
significant anymore (Fig. 13, A). Also levels of phosphorylated STAT5b were reduced 
by all three compounds and the phosphorylation of STAT5b in PDGF-BB treated 
sample was still significantly higher than in vehicle-treated sample. Interestingly, all 
three compounds showed about the same potency in reducing the phosphorylation of 
STAT5b after 1 h (Fig. 13, B). 
 
Fig. 13. Influence of I3MO, LiCl and AG490 on PDGF-BB-induced STAT3 and STAT5b 
phosphorylation after 1h.  
Serum-starved VSMC were pretreated with I3MO (5 µM), AG490 (25 µM) LiCl (20 mM) or vehicle (DMSO 
1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml) for 1 h. Cell lysates were prepared and 
subjected to western blot analysis for phosphorylation of STAT3 on Y705 (A) and phosphorylation of 
STAT5b on Y694 (B). Graphs show means of densitometrically analysed protein/tubulin (Tub) ratios of 
three independent experiments ± SEM. (n.s., not significant; *, p < 0.05**, p < 0.01, one-way ANOVA 
followed by Dunnett post-test versus PDGF treatment).  
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Finally, we examined the influence of all three compounds on phosphorylation of other 
protein kinases after stimulation with 10 ng/ml of PDGF-BB for 10 min, including 
phosphorylation of ERK and p38, which was found not to be affected by I3MO by 
Andrea Schwaiberger, who used 20 ng/ml of PDGF-BB.144 
Fig. 14 (A and B) shows that none of all three compounds was found to reduce 
phosphorylation of ERK and p38 after PDGF-BB stimulation for 10 min.  
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Fig. 14. Influence of I3MO, LiCl and AG490 on PDGF-BB-induced ERK and p38 phosphorylation 
after 10 min.  
Serum-starved VSMC were pretreated with I3MO (3 µM or 5 µM), AG490 (25 µM), LiCl (20 mM) or 
vehicle (DMSO 1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml) for 10 min. Cell lysates were 
prepared and subjected to western blot analysis for ERK (A) and p38 (B) phosphorylation. Tubulin (Tub) 
was used for loading control. Photographs show one representative blot out of three independent 
experiments. 
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3. Influence of I3MO, AG490 and LiCl on STAT3/STAT5b 
 target gene expression 
We showed that I3MO was able to inhibit phosphorylation of STAT3 on Y705 and 
phosphorylation of STAT5b on Y694 after stimulation with 10 ng/ml of PDGF-BB. To 
examine whether this is the pathway by which I3MO is reducing VSMC migration, we 
investigated the influence of I3MO on STAT3 and STAT5b target genes that are 
knowingly involved in migration. 
Recently, the expression of cPLA2 after PDGF-BB stimulation has been shown to 
directly depend on STAT3 activation in a JAK2-dependent manner.92 Furthermore, 
cPLA2 has been implicated in PDGF-BB and thrombin-induced VSMC migration.93,151 
Yellaturu et al. showed that expression of cPLA2 was highest after 16 h.92 
Hence, we chose a similar timeframe to check whether I3MO, AG490 and LiCl could 
reduce cPLA2 expression after stimulation with 10 ng/ml of PDGF-BB. Fig. 15 shows 
that AG490 reduced levels of cPLA2 as expected from the literature.92 In addition, 
I3MO and LiCl also reduced expression of cPLA2. 
 
Fig. 15. Influence of I3MO, LiCl and AG490 on PDGF-BB-induced cPLA2 expression.  
Serum-starved VSMC were pretreated with I3MO (5 µM), AG490 (25 µM), LiCl (20 mM), or vehicle 
(DMSO 1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml) for 15 h. Cell lysates were prepared 
and subjected to western blot analysis for cPLA2 expression. Graphs show means of densitometrically 
analysed protein/tubulin (Tub) ratios of three independent experiments ± SEM. (**, p < 0.01, one-way 
ANOVA followed by Dunnett post-test versus PDGF treatment).  
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In addition, cyclin D1 expression has been described to be promoted by STAT5b and 
STAT3 175-180 and also its implication in migration has been reported.181-183 Hence, we 
first studied whether PDGF-BB-induced cyclin D1 expression after stimulation for 6, 
15 and 20 h. We found that induction of cyclin D1 expression was increased after 
stimulation for 6 h (data not shown). We next examined the effects of I3MO, LiCl and 
AG490 on cyclin D1 expression after stimulation with 10 ng/ml PDGF-BB for 6 h. 
Fig. 16 shows that all three compounds significantly reduced cyclin D1 expression. 
 
Fig. 16. Influence of I3MO, LiCl and AG490 on PDGF-BB-induced cyclin D1 expression.  
Serum-starved VSMC were pretreated with I3MO (5 µM), AG490 (25 µM), LiCl (20 mM) or vehicle 
(DMSO 1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml) for 6 h. Cell lysates were prepared and 
subjected to western blot analysis for cyclin D1 expression. Graphs show means of densitometrically 
analysed protein/tubulin (Tub) ratios of three independent experiments ± SEM. (*, p < 0.05, one-way 
ANOVA followed by Dunnett post-test versus PDGF treatment).  
These data demonstrate that I3MO is able to interfere with the expression of 
STAT3/STAT5b-dependent promigratory target genes, cPLA2 and cyclin D1. Inhibitors 
of JAK2 and GSK-3 can mimic the I3MO phenotype. 
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4. Influence of I3MO and LiCl on cytoskeletal rearrangement 
After stimulation with chemotactic molecules, cells undergo an early cytoskeletal 
rearrangement. Protrusions as lamellipodia and filopodia form and actin monomers 
organize into thick actin filament bundles, named stress fibres.41 Also in smooth 
muscle cells, formation of stress fibres has been reported.184 Furthermore, stimulation 
with PDGF leads to actin-rich membrane ruffles,185 which are thought to be active 
sites of actin reorganization when located at the dorsal surface.186 
To study whether I3MO already affects these early events in cellular migration, we 
used fungal FITC-labeled phalloidin, which binds to polymerized actin, to visualize 
actin structures in our cells.148 In fibroblasts, cells have been seen to organize actin in 
lamellipodia and filopodia after 30 min. After 1 h, they have been observed to develop 
stress fibres.187 Therefore, we examined VSMC treated with vehicle, I3MO and LiCl 
and stimulated with 10 ng/ml of PDGF-BB for 1 h. 
Fig. 17 shows representative photographs of one experiment. We found, that PDGF-
BB induces stress fibres and membrane ruffling in VSMC after one hour. I3MO (5 µM) 
as well as LiCl (20 mM) seemed to reduce at least stress fibre formation. Although the 
photographs suggest that I3MO as well as LiCl interact with early signalling cascades, 
additional and more meaningful studies concerning the cytoskeleton are needed to 
confirm this observation. This experiment was carried out together with Irene Sroka, 
PhD. 
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Fig. 17. Influence of I3MO and LiCl on PDGF-BB-induced stress fibre formation.  
VSMC were cultivated on collagen-coated coverslips, serum-starved, pretreated with I3MO (5 µM) LiCl 
(20 mM) or vehicle (DMSO 1 %) for 30 min and stimulated with PDGF-BB (10 ng/ml) for 1 h. Cells were 
fixed and stained with FITC-labeled phalloidin. Samples were analysed with fluorescence microscope. 
Experiment was carried out together with Irene Sroka, PhD. 
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E. DISCUSSION 
1. Antimigratory activity of I3MO 
Before this thesis, an antiproliferative effect of I3MO on VSMC in cell culture has been 
shown in our lab. Cells were hereby arrested in G0/G1-phase. Additionally, neointima 
formation was reduced by I3MO in a cuff-induced neointima mouse model.144 Since 
proliferation and migration of VSMC are both crucial in the formation of 
atherosclerosis and restenosis (see chapter B, section 2.2), we here investigated the 
effect of I3MO on VSMC migration in a wound healing assay. We found that I3MO 
dose-dependently reduced VSMC migration after stimulation with PDGF-BB (see Fig. 
8). 
These data are consistent with previous findings of Irene Sroka in a Boyden-chamber 
model. In this assay, VSMC had to migrate actively through a porous membrane 
along a PDGF-gradient. Also in this assay, migration of VSMC after PDGF-BB 
stimulation was inhibited dose-dependently by I3MO.145 We therefore clearly 
demonstrated that I3MO inhibits PDGF-BB-induced migration of VSMC. 
To further investigate influences of I3MO on migration, we examined its effect on early 
cytoskeletal rearrangements. At least stress fibre formation seemed to be reduced 
(Fig. 17). Although the experiment suggests that I3MO interacts also with early 
cellular events essential for migration, further studies are needed to confirm this 
observation.  
Indirubins have been reported to inhibit cell migration in other cell types122,188, but the 
finding that I3MO is able to inhibit VSMC migration is novel and adds an important 
aspect to the potential anti-atherosclerotic and anti-restenotic activity of I3MO. 
2. Possible antimigratory targets of I3MO 
2.1. Phosphorylation of STATs 
We were further interested in the molecular target of I3MO responsible for impaired 
migration after PDGF-BB stimulation. As already mentioned, phosphorylation of 
protein kinases, including ERK, p38 and Akt, was not affected by I3MO after 
stimulation with 20 ng/ml of PDGF-BB.144 As we used 10 ng/ml of PDGF-BB in our 
setting (see chapter D, section 1.1.), we repeated the experiment and found that also 
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in this concentration PDGF-BB increased phosphorylation of protein kinases, 
including p38 and ERK. I3MO did not abrogate the phosphorylation (Fig. 14). 
Furthermore, previous work in our lab showed that I3MO completely inhibited 
phosphorylation of STAT1/3/5 and partially inhibited phosphorylation of STAT6 after 
stimulation with 20 ng/ml of PDGF-BB.144  
Among other cellular processes, including proliferation, apoptosis, and differentiation, 
STATs have been reported to be involved in cell migration.189 In particular STAT3 and 
STAT5b have been demonstrated to be essential in cell migration167-171, including in 
VSMC migration.91,93,151,172 In our experiments, using 10 ng/ml of PDGF-BB, 
phosphorylation of STAT3 and STAT5b was also significantly increased compared to 
the unstimulated sample, and I3MO abrogated phosphorylation (Fig. 11). 
Furthermore, we found a reduced expression of STAT3 and STAT5b target genes, 
including cPLA2 and cyclin D1, both known to be involved in migration. cPLA2 is an 
enzyme involved in the hydrolysis of membrane glycerophospholipids to free 
arachidonic acid, a precursor of prostaglandins, leucotrienes and other eicosanoids.190 
Previously, expression of cPLA2 has been described to be up-regulated after 
stimulation with PDGF-BB in VSMC and the enhanced expression has been proposed 
to be JAK2/STAT3-mediated.92 Furthermore, cPLA2 has been found to be involved in 
VSMC migration after stimulation with PDGF-BB and thrombin.93,151 Selective 
inhibitors of cPLA2 reduced VSMC motility93,151, whereas arachidonic acid rescued 
VSCM motility after inhibition of JAK293 or expression of a dominant negative 
STAT3.151 Concordant with these studies, we found that expression of cPLA2 was 
enhanced after stimulation with PDGF-BB for 15 h and I3MO reduced this effect (Fig. 
15). 
In addition, we found that I3MO reduced cyclin D1 expression after stimulation with 
PDGF-BB for 6 h (Fig. 16). Cyclin D1 is a protein centrally involved in the 
development of human cancers.191 In addition, its implication in cell migration has 
been reported181-183, and STAT3 and STAT5b have been described in several studies 
to promote cyclin D1 expression.175-180 In VSMC, PDGF-BB has been reported to 
induce cyclin D1 expression after 8 h and this effect was abolished by dominant 
negative STAT5b.91 
Taken together, our results demonstrate that I3MO inhibits STAT3 and STAT5b 
phosphorylation in VSMC stimulated with 10 ng/ml of PDGF-BB and that PDGF-BB 
induced expression of the promigratory proteins cyclin D1 and cPLA2. But whether 
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these activities of I3MO truly account to its observed antimigratory effect, needs to be 
shown. A clear evidence for the causal connection between inhibition of STAT 
phosphorylation and inhibition of migration by I3MO is missing. Current investigations 
in the lab working with a constitutively active form of STAT3 aim to provide the proof 
for this causality. 
2.2. The JAK-signaling pathway 
Assuming STATs as effectors of I3MO´s antimigratory actions on VSMC, we were 
further interested in possible upstream activators of STATs as direct targets of I3MO. 
Although it is well established that STATs are activated by JAKs after cytokine 
activation, the upstream activators after growth factor stimulation are less clear.84 
However, JAK2 has been demonstrated to induce STAT phosphorylation after PDGF 
stimulation in SMC.84,92,93,192 JAK2 inhibition has been found to reduce SMC 
proliferation84,192 and migration93 after stimulation with PDGF. Furthermore, JAK2 
inhibitors as well as dominant negative mutants of JAK2, have been found to reduce 
STAT3 phosphorylation 84,92,93, -translocation, -DNA-binding activity and -reporter 
gene expression92,93 after stimulation with PDGF in SMC. We therefore compared 
AG490, a chemical inhibitor of JAK2152-154, to I3MO, regarding its intracellular actions. 
We showed that AG490 effectively blocked VSMC migration after PDGF-BB 
stimulation (Fig. 9). Furthermore, concordant with the literature, 84,92,192 we found that 
phosphorylation of STAT3 on Y705 was significantly reduced after stimulation with 10 
ng/ml of PDGF-BB by higher concentrations of AG490 (50 µM) (Fig. 12). However, 
AG490 did not abrogate phosphorylation of STAT3 to the same extent as I3MO did. 
Interestingly, we found that also phosphorylation of STAT5b on Y694 was reduced by 
AG490 even at lower concentrations (Fig. 12). Phosphorylation of other protein 
kinases, including p38 and ERK, was not inhibited by AG490 after stimulation with 10 
ng/ml of PDGF-BB (Fig. 14). 
Finally, AG490 also reduced STAT3 and STAT5b promigratory target gene 
expression, including cPLA2 and cyclin D1, exactly mimicking effects of I3MO (Fig. 15 
and 16). 
Although I3MO to our knowledge has never been described as inhibitor of JAK2, but 
only as an inhibitor of JAK1 in vitro143, we found marked similarities in the way of 
cellular actions of AG490 and I3MO. However, in preliminary experiments we had 
found in our lab that JAK2 phosphorylation was not increased after stimulation with 
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PDGF-BB in VSMC. This finding argues against JAK2 as upstream mediator of 
PDGF-induced STAT phosphorylation.144 Since in the literature JAK2 phosphorylation 
after PDGF stimulation in VSMC has been reported92,93,192, definitely more 
experiments are needed to resolve the issue of JAK2 as a possible upstream 
signaling molecule of STAT3 and STAT5b in our VSMC and to elucidate whether 
I3MO and AG490 share the same signaling pathway or the same target. 
Next to direct inhibition of JAK2 activity, I3MO could also interfere with signaling steps 
upstream of JAK2 activation. Possible candidate targets for I3MO could then be ROS 
(reactive oxygen species) or Src. Both, ROS193,194 and Src64,65 have been shown to 
promote migration of VSMC. Furthermore, PDGF-induced JAK2 activation has been 
reported to be ROS-dependent 192,195,196 and/or Src-dependent84,197.  
VSMC contain different sources of ROS, including xanthine oxidases, the 
mitochondrial respiratory chain, lipoxygenases, nitric oxide synthases and NADPH 
oxidases (NOXes).198 In the literature, NOX5 has been shown to be required for JAK2 
activation after PDGF stimulation in human airway smooth muscle cells. PDGF-
induced phosphorylation of JAK2 was abolished by an unselective inhibitor of all Nox-
isoforms199, Diphenylen iodonium (DPI).192 Additionally, JAK2 has been reported to be 
activated by exogenous H2O2, a molecule of the ROS-group200, in fibroblasts195 and 
VSMC196. Notably, previous work in our lab has shown that I3MO reduced PDGF-BB-
increased ROS-production in VSMC.144 Furthermore, exogenous H2O2 was sufficient 
to increase STAT3 phosphorylation in VSMC and this effect was abolished by 
I3MO.144 Earlier experiments in our lab also showed that PDGF-BB-stimulated VSMC 
migration as well as STAT3 phosphorylation was reduced by DPI145. 
Furthermore, preliminary experiments in our lab showed that the Src inhibitor 
SU6656201 reduced PDGF-BB-induced VSMC migration145, and STAT3/STAT5b 
phosphorylation.144 The observation that the JAK2 inhibitor AG490 and the Src 
inhibitor SU6656 had similar effects, is not completely unexpected: in the literature, it 
is proposed that STAT activation by PDGF requires both, JAKs and Src kinases and 
that the two kinases may share a common pathway in different cell types,202,203 
including human airway smooth muscle cells.84 As already mentioned, Src has also 
been presumed to be an upstream activator of JAK2 after PDGF stimulation.84,197 
To sum up, all these experiments make it plausible that AG490 and I3MO may affect 
at least proteins of a common signaling axis. However, defining the exact signaling 
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steps induced by PDGF-BB in VSMC and affected by I3MO remains an open and 
interesting question. 
2.3. The GSK-3 signaling pathway 
GSK-3 is an enzyme related to glycogen metabolism. Furthermore, in the last years it 
has become clear that the kinase is involved in a number of diseases, including 
Alzheimer´s disease, cancer, and inflammation. In addition, it has been reported to be 
strongly involved in cell migration. I3MO has been described as a GSK-3 inhibitor in 
several cell lines (see chapter B, section 6.3.2.). 
Furthermore, it has been reported that STAT3 phosphorylation after stimulation with 
IFN-γ and LPS and STAT5 phosphorylation after stimulation with interferon-α (IFN-α), 
IFN-γ and Granulocyte-macrophage colony-stimulating factor (GM-CSF) is GSK-3-
dependent in different cell lines. Among other GSK-3 inhibitors, I3MO, 6-bromo-I3MO 
and LiCl were shown to inhibit STAT3 and STAT5 phosphorylation in these cell 
types.173 
We therefore investigated the effects of LiCl, a known GSK-3 inhibitor159-162, on VSMC 
migration after stimulation with PDGF-BB. We found that LiCl completely reduced 
VSMC migration and that this effect was not simply due to osmotic changes (Fig. 10). 
Additionally, LiCl exerted similar effects as I3MO on early cytoskeletal rearrangements 
after stimulation with PDGF-BB (Fig. 17).  
Although we failed to demonstrate that LiCl reduced STAT3 or STAT5b 
phosphorylation after 10 min (Fig. 12), we showed that phosphorylation of both STATs 
was reduced after 1 hour (Fig. 13). Phosphorylation of other protein kinases, including 
p38 and ERK, were not inhibited by LiCl (Fig. 14). 
Additionally we showed that STAT3 and STAT5b promigratory target gene 
expression, including cPLA2 and cyclin D1, was reduced by LiCl (Fig. 15 and Fig.16). 
Due to the different kinetics of STAT3 and STAT5b inhibition (10 min vs. 1 h) we are 
prone to exclude that I3MO and LiCl may share one single target and/or one single 
mode of action. However, we cannot rule out that I3MO may additionally inhibit GSK-3 
in VSMC after PDGF-BB stimulation. Further studies would be interesting to elucidate 
whether I3MO can influence GSK-3 activation in VSMC or whether a constitutively 
active form of GSK-3 could overcome the antimigratory effect of I3MO.  
Lithium´s effect on VSMC migration after PDGF-BB stimulation has not been reported 
so far. We therefore investigated also its influence on VSMC proliferation. Indeed, 
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Irene Sroka showed that LiCl led to an accumulation of cells in G1-phase of the cell 
cycle, similar to the effect elicited by I3MO.145 
The finding that a GSK-3 inhibitor inhibits migration and proliferation of VSMC is 
somehow conflicting: although GSK-3 inhibition has been reported to have 
antimigratory effects in other cell types122,128,164-166, expression of a constitutively active 
nonphosphorytable mutant of GSK-3 has been demonstrated to reduce VSMC 
migration after PDGF-BB stimulation.129 Moreover, GSK-3 has been proposed to 
suppress SMC proliferation and this effect was reversed by PDGF.130,131  
We cannot exclude at this stage that the observations made with LiCl in our cells are 
not due to inhibition of other targets of LiCl, including inositol monophosphate 
phosphatase (IMP) or inositol polyphosphate-1-phosphatase (IPP), two enzymes 
often referred as to be inhibited by LiCl.61,204,205 Nevertheless, the effect of LiCl was 
impressive and it would be interesting elucidate the role of LiCl in PDGF-BB-induced 
proliferation and migration of VSMC. 
Summarizing our results, we clearly demonstrated that in addition to proliferation and 
to neointima formation in vivo, I3MO inhibits PDGF-BB-induced migration. Although 
the direct molecular target remains unclear, these effects of I3MO may offer a 
therapeutic potential in the treatment of atherosclerosis and restenosis, including the 
application in drug-eluting stents.  
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F. SUMMARY 
Previous work in our lab showed that I3MO is able to inhibit PDGF-BB-induced VSMC 
proliferation. Furthermore, the compound was able to reduce neointima formation in 
vivo in a mouse model (experiments performed in cooperation with Prof. Binder, 
Medical University of Vienna). Finally, I3MO inhibited phosphorylation of STATs 
without interfering with other common early signaling events. 
Both, migration and proliferation of VSMC are responsible in the early onset of 
atherosclerosis. We therefore intended to additionally investigate the antimigratory 
properties of I3MO. The present work showed that I3MO was indeed able to inhibit 
PDGF-BB-induced migration of VSMC. It was also able to interfere with early 
cytoskeletal rearrangements. I3MO abolished STAT3 and STAT5b phosphorylation 
after stimulation with 10 ng/ml of PDGF-BB, thereby indicating that these STATs may 
be involved in PDGF-BB-induced VSMC migration. We found that I3MO also reduced 
expression of the STAT3 and STAT5b target genes, cPLA2 and cyclin D1, which have 
been described to be involved in migration. To further elucidate the underlying 
mechanisms of I3MO-effects, we compared cellular actions of I3MO to a chemical 
inhibitor of JAK2, AG490 and to an inhibitor of GSK-3, LiCl. We found that both 
AG490 and LiCl inhibited PDGF-BB-induced VSMC migration. AG490 further reduced 
STAT3 and STAT5b phosphorylation after PDGF-BB stimulation. Both compounds 
reduced STAT3 and STAT5b target gene expression. Although we found considerable 
similarities between AG490 and I3MO regarding their intracellular actions, the exact 
cellular target of I3MO remains unclear.  
However, our studies affirm I3MO as a possible agent in the treatment of 
vasoproliferative diseases, including atherosclerosis and restenosis.  
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1. Abbreviations 
A 
AhR   Aryl hydrocarbon receptor 
AMPK   AMP-activated protein kinase  
APC   Adenomatous polyposis coli protein 
APS   Ammonium persulfate  
Arf6   ADP-ribosylation factor 6  
Arp2/3 complex  Actin-related protein 2/3 complex 
B 
bFGF   Basic fibroblast growth factor 
BSA   Bovine serum albumin 
C 
CAK   CDK-activating kinase  
CB   Cytoskeleton buffer 
CDKs   Cyclin-dependent kinase  
cPla2   Cytosolic phospholipase A2 
D 
DAG   Diacylglycerol 
DMEM   Dulbecco´s Modified Eagle Medium  
DMSO   Dimethyl sulfoxide  
DPI   Diphenylene iodonium  
E 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetreacetic acid 
EGF   Epidermal growth factor 
EGTA   Ethylene glycol tetraacetic acid 
ERK   Extracellular signal-regulated kinase 
F 
FAK   Focal adhesion kinase  
G 
GAP   GTPase-activating protein 
GEF   Guanine nucleotide exchange factor 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GSK-3   Glycogen synthase kinase-3 
H 
HEPES   Hydroxyethylpiperazineethanesulfonic acid 
APPENDIX 
85 
 
HRP   Horseradish peroxidase 
I 
I3MO   Indirubin-3´-monoxime  
IFN-α   Interferon-α 
IFN-γ   Interferon-γ 
IGF-1   Insulin-like growth factor- 1  
IMPase   Inositol monophosphate phosphatase  
IP3   Inositol-1,4,5-trisphosphate 
IPPase   Inositol polyphosphate-1-phosphatase 
J 
JAK   Janus kinase 
JNK   C-Jun N-terminal kinase 
L 
LCK   Lymphocyte kinase  
LDL   Low density lipoprotein 
LPS   Lipopolysaccharide 
M 
MAPK   Mitogen-activated protein kinase 
Mc   Monoclonal 
MCP-1   Monocyte chemoattractant protein-1 
MEK   MAPK/ERK kinase 
MES   2-N-morpholino-ethanesulfonic acid 
MIF   Macrophage inhibitory factor 
MK2   MAPK activated protein kinase 2 
MKK   MAPK kinases  
MLCK   Myosin light chain kinase  
MLCP   MLC phosphatase  
MMP   Matrix metalloproteinase 
MTOC   Microtubule organizing centre 
N 
NO   Nitric oxide 
NOX   NADPH oxidase 
P 
p38   P38 MAP kinase 
PAA   Polyacrylamide  
PBS   Phosphate buffered saline  
Pc   Polyclonal 
PCI   Percutaneous coronary intervention 
PDGF   Platelet derived growth factor  
PI3K   Phosphatidylinositol 3-kinase 
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PIP2   Phosphatidylinositol-4,5-bisphosphate  
PIP3   Phosphatidylinositol-3,4,5–trisphsospate 
PKC   Proteinkinase C 
PLC-γ   Phospholipase C-γ 
PLD   Phospholipase D 
PMSF   Phenylmethanesulphonylfluoride 
PTA   Percutaneous transluminal angioplasty  
R 
ROCK   Rho-associated, coiled-coil-containing protein kinase 
ROS   reactive oxygen species 
RTK   Receptor tyrosine kinase  
S 
SDS   Sodium dodecyl sulfate  
SGK   Serum- and glucocorticoid-induced kinase  
SH2   Src homology 2 domain 
SHP-2   SH2-containing protein-tyrosine phosphatase 
SOCS   Suppressor of cytokine signaling  
Src   Src family tyrosine kinase  
STAT   Signal transducer and activator of transcription 
T 
TBS-T   Tris-buffered saline/Tween 20 buffer 
TEMED   Tetramethylethylenediamine 
TGF   Transforming growth factor 
TIMP   Tissue inhibitor of metalloproteinases 
TNF-β   Tumor necrosis factor-β 
TRIS   Trihydroxymethylaminomethane 
U 
uPA   Urokinase plasminogen activator  
V 
VSMC   Vascular smooth muscle cell 
W 
WASP   Wiskott-aldirch syndrome protein  
WAVE   Verprolin-homologous protein 
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2. Alphabetical list of companies 
Beckmann Coulter  Fullerton, CA, USA 
Biorad laboratories  Hercules, CA, USA 
Broad Institute   Cambridge, MA, USA 
Calbiochem   La Jolla, CA, USA 
Carl Roth   Karlsruhe, Germany 
Cell signaling    Danvers, MA, USA 
Fujifilm    Tokyo, Japan 
GraphPad Software Inc  San Diego, CA, USA 
Lonza Group Ltd.   Basel, Switzerland 
New England Biolabs  Beverly, MA, USA 
Olympus Europe GmbH  Hamburg, Germany 
Santa Cruz   Santa Cruz, CA, USA 
Sigma Aldrich   St. Louis, MO, USA  
TECAN    Mannedorf, Switzerland 
Upstate    Charlottesville, VA, USA 
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